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   Vitamin	  E	  and	  selenium	  are	  proposed	  to	  affect	  the	  oxidant-­‐antioxidant	  balance	  in	  the	  body	  and	  thus	  to	  affect	  human	  health	  outcomes.	  The	  effects	  of	  these	  nutrients	  on	  rate	  of	  decline	  in	  lung	  function	  were	  assessed	  in	  the	  Respiratory	  Ancillary	  Study	  (RAS)	  to	  the	  Selenium	  and	  Vitamin	  E	  Cancer	  Prevention	  Trial	  (SELECT),	  a	  randomized	  placebo-­‐controlled	  trial	  of	  men	  assigned	  to	  vitamin	  E	  (400	  IU/day	  all	  rac-­α-­‐tocopheryl	  acetate)	  and/or	  selenium	  (200	  µg/day	  L-­‐selenomethionine).	  This	  dissertation	  reports	  the	  effects	  of	  supplementation	  on	  a	  biomarker	  of	  oxidative	  stress	  and	  on	  changes	  in	  plasma	  nutriture,	  and	  investigates	  the	  mediation	  and	  modification	  of	  the	  effect	  of	  supplementation	  on	  rate	  of	  decline	  in	  lung	  function.	  	  Compared	  to	  placebo,	  vitamin	  E,	  alone	  and	  combined	  with	  selenium,	  lowered	  a	  biomarker	  of	  oxidative	  stress,	  urine	  F2-­‐Isoprostanes,	  by	  21%	  (p=0.0231)	  and	  9%	  (p=0.3738),	  respectively.	  Treatment	  with	  vitamin	  E	  attenuated	  the	  age-­‐related	  decline	  in	  lung	  function,	  but	  this	  effect	  was	  not	  mediated	  by	  lowering	  of	  F2-­‐Isoprostanes.	  There	  was	  no	  evidence	  of	  selenium	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effects	  on	  F2-­‐Isoprostanes	  (8%	  higher	  F2-­‐IsoPs	  compared	  to	  placebo;	  p=0.5217).	  	  Given	  no	  overall	  effect	  of	  selenium	  on	  rate	  of	  decline	  in	  lung	  function,	  a	  plausibility	  analysis	  considered	  whether	  treatment	  effects	  were	  limited	  to	  men	  with	  lower	  selenium	  status	  at	  study	  baseline.	  There	  was	  no	  difference	  in	  the	  effect	  of	  selenium	  on	  lung	  function	  by	  baseline	  plasma	  selenium	  concentration,	  either	  considering	  selenium	  deficiency,	  or	  plasma	  selenium	  as	  a	  continuous	  variable.	  	  The	  effect	  of	  vitamin	  E	  on	  lung	  function	  is	  postulated	  to	  reflect	  effects	  in	  the	  lung	  compartment,	  and	  plasma	  vitamin	  E	  concentrations	  are	  assumed	  to	  reflect	  target	  tissue	  concentrations.	  We	  investigated	  factors	  associated	  with	  the	  change	  in	  plasma	  alpha-­‐tocopherol	  in	  response	  to	  supplementation	  in	  the	  RAS.	  Race	  was	  the	  primary	  factor	  identified:	  specifically,	  the	  change	  in	  plasma	  alpha-­‐tocopherol	  concentrations	  in	  response	  to	  alpha-­‐tocopherol	  supplementation	  was	  about	  50%	  less	  in	  African	  Americans	  compared	  to	  European	  Americans.	  	  	  
Vitamin	  E	  reduces	  systemic	  oxidative	  stress	  and	  attenuates	  age-­‐related	  decline	  in	  lung	  function.	  Given	  differences	  in	  plasma	  response	  to	  supplementation,	  future	  studies	  considering	  baseline	  nutriture	  and	  indicators	  of	  nutrient	  absorption,	  transport	  and	  metabolism	  would	  contribute	  to	  a	  fuller	  understanding	  of	  vitamin	  E	  effects	  on	  health	  outcomes.	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CHAPTER 1 
INTRODUCTION 
 
Lung function measurements provide insights into lung health, which is predictive 
of mortality in adults, and are used to diagnose and stage the severity of chronic 
obstructive pulmonary disease (COPD). COPD, characterized by irreversible air flow 
limitation and inflammation, is the third leading cause of death in the United States and 
leads to morbidity, mortality, and contributes to increased health care costs (1). There is no 
cure for COPD, and although currently available therapies alleviate symptoms, no current 
treatments are efficacious in slowing the rate of decline in lung function(2-4), which is 
steeper in individuals with COPD. Smokers are at greatest risk of COPD and smoking 
cessation is the primary preventive approach that attenuates rate of lung function decline, 
however, cross-sectional lung function is lower in smokers even after cessation. Given that 
never and former smokers may also develop COPD, and given that about 20% of the US 
population persists in smoking, interventions that attenuate rate of decline in lung function 
are needed.  
Observational epidemiological studies of dietary antioxidant intake, serum 
antioxidant concentration, and lung outcomes report that lower levels of antioxidant 
defense are associated with decreased lung function(5-11), supporting the hypothesis that 
oxidant-antioxidant balance is critical in maintaining lung health; thus, we hypothesized 
that supplemental antioxidants protect lung tissue from oxidative damage and attenuate 
rate of decline in lung function. Vitamin E and selenium, the two nutrients addressed 
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herein, are antioxidant nutrients hypothesized to affect lung function primarily through 
mechanisms related to the lowering of oxidative stress. 
 This dissertation research used data from the Respiratory Ancillary Study 
(RAS)(12), an ancillary study to The Selenium and Vitamin E Cancer Prevention Trial 
(SELECT)(13). SELECT began in 2001 and randomized 35,433 male participants to 400 mg 
α-tocopherol (vitamin E) + selenium (Se) placebo, vitamin E placebo + 200 µg 
Selenomethionine, 400 mg α-tocopherol+ 200 µg Selenomethionine, or vitamin E placebo + 
Se placebo; the primary endpoint for SELECT was the prevention of prostate cancer, 
whereas the primary endpoint for the RAS was rate of decline in pulmonary function. RAS 
was comprised of a subsample of 2,920 SELECT participants which was purposefully 
enriched with current cigarette smokers to test hypotheses in the subset of smokers; 
further details of RAS (NCT00241865) and SELECT (NCT00006392) are published 
elsewhere(12, 13). 
Vitamin E is an essential fat-soluble vitamin that primarily functions as a chain-
breaking antioxidant in humans, maintaining the integrity of cell membranes by 
eliminating free radicals(14) and thus preventing damage from reactive oxygen species 
(ROS). Vitamin E is comprised of four tocopherols and four tocotrineols which are 
distinguished by their chemical structures. Gamma(γ)-tocopherol is the main dietary form 
of vitamin E(14), however alpha(α)-tocopherol is the only form recognized to meet human 
requirements largely due to the preferential binding of this form by the α-tocopherol 
transfer protein (α-TTP) in the liver(15) and thus retention of this form in the plasma. 
Unless otherwise specified, vitamin E hereafter refers to α-tocopherol.  
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Selenium also has antioxidant properties and is an important constituent in 
protective enzymes and amino acids, such as selenocysteine and selenomethionine(16). 
Prior studies investigating the effects of selenium on health outcomes are mixed, but 
suggest that benefits may be limited to individuals with low baseline selenium status(17).  
Previous randomized controlled trials of the effect of antioxidants on respiratory 
outcomes have produced mixed results(18-21), with most finding no effect of vitamin E on 
lung health outcomes. The lack of effects in past studies may be affected by 
misclassification of disease status, which would limit power to detect true associations. For 
example, SELECT used self-reported physician’s diagnosis of COPD to define the COPD 
endpoint; self-reported diagnosis of COPD includes only a subset of individuals in the 
population with obstructive lung disease(22), and therefore studies that rely on self-
reported outcomes are comprised of only a fraction of all outcomes. Previous work shows 
that patients with milder disease are less likely to be diagnosed(23), which may lead to 
biased estimates of preventive effects of intervention. Additionally, the duration of prior 
intervention studies may have been too short thus limiting the ability of the trial to 
demonstrate significant protective effects of vitamin E on COPD incidence, symptoms, 
and/or death or hospitalization from respiratory illness. If oxidative stress is truly reduced 
by vitamin E and such reduction alters disease risk, then studies of longer duration using 
more robust definitions of COPD (such as spirometry-defined COPD) may be needed in 
order to detect effects of interest. Of note, the one study reporting a significant finding of a 
protective effect of vitamin E had twice the duration (9.8 years)(18) in comparison to 
studies reporting no effect of intervention, which supports the idea that limited follow-up 
may have reduced the ability of prior studies to detect a significant effect of vitamin E on 3
  
lung outcomes.  Lung function can be assessed by various lung function parameters 
including FEV1 (forced expiratory volume in the first second of exhalation), and FEF25-75 
(forced expiratory flow rate between 25-75% of the forced vital capacity (FVC)). Smokers 
have steeper rates of decline in FEV1 and are at increased risk of COPD. Attenuating the rate 
of decline in lung function may have a significant public health impact, given that steeper 
rate of decline is independently associated with mortality(24-29) and with increased risk 
of COPD, but no currently available therapies (other than smoking cessation) attenuate the 
rate of decline(2-4). The RAS to SELECT previously established a protective effect of 
vitamin E (vitamin E alone or vitamin E combined with selenium) on rate of decline in lung 
function(12) rate of decline in FEV1 was attenuated by 6 mL/yr for FEV1 (p=0.188), and 
rate of decline in FEF25-75 was attenuated by 13mL/sec/yr (p=0.212); the latter effect was 
statistically significantly stronger in smokers (pinteraction=0.0513), the subgroup 
hypothesized to be at greatest risk of COPD and steep rate of decline. RAS found no effects 
of selenium on lung function endpoints.  
The epidemiologic framework for this dissertation research is presented in Figure 1. 
This research addresses the effects of vitamin E and selenium on the gold-standard 
biomarker of in vivo oxidative stress, namely urine F2-isoprostanes (F2-IsoPs) (30), and 
further investigates whether the effect of vitamin E intervention on rate of decline in lung 
function is mediated by lowering of this biomarker. Past trials of antioxidant nutrients on 
biomarkers of oxidative stress and lung function have been limited by small sample sizes, 
short trial duration, cross-sectional and non-randomized designs, varying and sometimes 
unspecified nutrient forms and dosages, and ill-defined sample characteristics. This study 
improves upon past designs and offers more definitive evidence of the antioxidant effects 4
  
of vitamin E through utilization of a gold-standard biomarker of oxidative stress within a 
large, long-term randomized trial, and offers a more comprehensive investigation of the 
mechanism of action by investigating mediation of the effect of supplementation by F2-
IsoPs. 
Furthermore, this dissertation thoroughly considers all effects of these nutrients, 
including analyses of baseline levels of vitamin E and selenium. We hypothesized that 
individuals with lower baseline levels of a nutrient would have greater benefit from 
supplementation with that nutrient, and thus greater attenuation in rate of decline in lung 
function would be expected in individuals with lower nutritional status at baseline. Since 
plasma vitamin E is known to plateau with higher levels of supplementation and given that 
past trials of selenium indicated that effects of selenium were limited to participants with 
low baseline selenium(17), the consideration of individual nutriture at the study baseline is 
important for developing a fuller understanding of nutrient effects. 
Finally, this dissertation addresses the effect of vitamin E supplementation on 
plasma vitamin E levels. Since any effect of vitamin E on health outcomes, including lung 
function and COPD, is proposed to act by transport of vitamin E through the plasma to the 
target tissue, individuals with a greater increase in plasma vitamin E in response to 
supplementation may experience a greater benefit from the intervention. It has been 
shown that plasma response to vitamin E supplementation is highly variable between 
individuals, but stable within an individual over time (thus, low intra-individual 
variability). For this reason, there is interest in identifying particular characteristics that 
may contribute to differential plasma response; such characteristics would also be
5
  
Figure 1. Epidemiologic Framework1 
 
1 This dissertation investigates the effects of selenium and vitamin E on the oxidative stress biomarker (urine F2-Isoprostanes) and rate of 
decline in lung function. This diagram is simplified to show only vitamin E supplementation, since only vitamin E is addressed in relation to 
change in the nutrient biomarker (plasma alpha-tocopherol levels). Baseline nutrition is measured as baseline plasma nutrient levels (alpha-
tocopherol and selenium). 
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expected to contribute to differential functional benefit from supplementation. Some cross-
sectional associations have been reported, but the research reported herein addresses a 
gap in the literature by using a long-term randomized controlled trial with a high 
percentage of African Americans, who are far less well-studied, and indeed are notably 
absent from a prior large vitamin E trial(21). Furthermore, this research adds new 
information by a thorough consideration of both α- and γ-tocopherol. 
While the research aims addressed in this dissertation focus on lung function 
phenotypes (rate of decline) and do not directly address the effect of nutritional and/or 
environmental factors on COPD, the oxidant-antioxidant balance is critical in maintaining 
lung health and an imbalance is proposed to be a key factor in COPD risk. Additionally, 
spirometry (pulmonary function testing) is the cornerstone of COPD diagnosis, and 
individuals with steeper rates of lung function decline are at greatest risk of developing 
COPD. Thus, any effects of these nutrients on oxidative stress and/or pulmonary function 
suggests the potential importance of these nutrients as preventives for COPD. Since COPD 
is an incurable disease with increasing prevalence and this dissertation addresses gaps in 
the literature, this dissertation contributes meaningful new information to the scientific 
body of knowledge about lung function, COPD, and oxidative stress. 
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Abstract 
Introduction: Oxidative stress contributes to rate of decline in lung function, specifically 
forced expiratory volume in the first second (FEV1), and progression of chronic obstructive 
pulmonary disease (COPD). Current cigarette smokers without COPD were studied to test 
the hypothesis that supplementation with nutrients with antioxidant properties mitigates 
oxidative stress, which leads to functional effects on lung health manifested as an 
attenuated rate of decline in FEV1. 
Methods: In a randomized placebo controlled trial of vitamin E (400 IU/d all rac-alpha-
tocopheryl acetate) and selenium (200 µg/d L-selenomethionine), urine 8-iso-
prostaglandin F2-alpha (F2-IsoPs), an oxidative stress biomarker, was measured in 312 
current smokers after thirty-six months on study. The effect of supplements on F2-IsoPs 
and the mediation of supplement effects on lung function by F2-IsoPs were investigated.  
Results: Compared to placebo, vitamin E, alone and combined with selenium, lowered 
urine F2-IsoPs by 21% (p=0.0231) and 9% (p=0.3738), respectively; there was no effect of 
selenium alone.  Higher F2-IsoPs were associated with lower FEV1, (β=-95 mL per unit 
increase in lnF2-IsoP; p=0.0679), although there was no evidence of an association with 
rate of decline in FEV1 (p=0.7922). Treatment with vitamin E attenuated rate of decline in 
FEV1 by 22 mL/year (p=0.1453), but there was no evidence that this effect was mediated 
by lowering of urine F2-IsoPs. 
Conclusions: Vitamin E decreases systemic oxidative stress, however, a tissue-specific 
biomarker may be needed to fully understand the mechanisms underlying the effect of 
vitamin E supplementation on lung function in smokers.  
  12
Introduction  
 Oxidative stress, an imbalance between pro-oxidants and antioxidants, is 
hypothesized to play a role in the pathogenesis of chronic obstructive pulmonary disease 
(COPD). COPD is characterized by increased inflammation and irreversible airflow 
limitation caused by lung tissue damage. Cigarette smoking, the primary risk factor for 
COPD, generates reactive oxygen species (ROS), which oxidize membrane phospholipids 
and lead to tissue damage and/or cell death(1). Oxidants, including those from cigarette 
smoke, also play a role in the molecular mechanisms that control lung inflammation(2).  
F2-isoprostanes (F2-IsoPs) are the gold-standard biomarker of in vivo oxidative 
stress(3); these prostaglandin-like bioactive compounds are biosynthesized in vivo by free-
radical-catalyzed lipid peroxidation of arachidonic acid(4). 8-iso-prostaglandin F2-alpha (8-
iso-PGF2α, 15-F2t-isoprostane) is a chemically stable isomer of F2-IsoPs and a reliable 
marker of oxidative stress in urine and plasma(5); elevations are associated with a wide 
range of diseases(6), and F2-IsoPs increase with smoking(7, 8) and COPD(9-12). 
Heritability of F2-IsoPs is estimated at 10%(13), thus environmental factors are the 
primary determinant of inter-individual variability in F2-IsoPs.  
 Observational studies consistently report that diets high in fruits and vegetables 
reduce the risk of chronic disease(14), and studies of lung outcomes are consistent with 
this overall trend. Thus, increased consumption of antioxidant-rich foods and higher 
concentrations of serum biomarkers of nutrients with antioxidant properties are 
associated with fewer COPD symptoms and better lung function(15, 16). Assuming 
antioxidant nutrients contribute to a causal mechanism lowering the risk of poor lung 
outcomes, establishing that nutrient intake leads to lower oxidative stress would provide 13
important data for causal inference. Prior studies do not comprehensively investigate the 
effect of antioxidant nutrients on a biomarker of lipid peroxidation such as F2-IsoPs in the 
context of a causal chain leading to changes in outcomes.  
Small vitamin E intervention studies assessing effects on F2-IsoPs report mixed 
results. Vitamin E had no effect on F2-IsoPs in five moderate smokers (given 100 IU/d, 
form unspecified) or seven heavy smokers (given 800 IU/d, form unspecified) over five 
days, but vitamin E in combination with vitamin C lowered F2-IsoPs by 22%(17). In forty-
six cigarette smokers, vitamin E (at doses of 300, 600, and 1200 mg/d all rac alpha (α)-
tocopheryl acetate) had no effect on F2-IsoPs during a three-week intervention(18).  In a 
six-month randomized, double-blind, placebo-controlled trial in eighty overweight 
subjects, natural vitamin E (800 IU/d for three months, followed by 1200 IU/d for 3 
months, all-natural RRR d-α-tocopherol), which has twice the bioavailability of synthetic 
vitamin E(19), reduced F2-IsoPs by 11%(20), suggesting the importance of trial duration 
and/or form of vitamin E supplement. In a randomized trial of two months duration, 
nonsmokers on vitamin E (800 IU/day, all-natural RRR d-α-tocopherol) had a 4% reduction 
in plasma F2-IsoPs, with greater reduction in individuals with higher baseline levels of 
oxidative stress(21), indicating the importance of potential to benefit in considering 
nutrient effects. 
Selenium also has antioxidant properties and is increasingly recognized as an 
important constituent in protective enzymes and amino acids, including selenocysteine and 
selenomethionine(22). Higher selenium status and selenium supplementation are 
associated with better health outcomes, however results of prior intervention studies are 
mixed and benefits may be limited to individuals with low baseline selenium status(23). 14
Few published studies investigate selenium intervention in relation to F2-IsoPs. One 
observational study among Swedish men reported significantly lower plasma F2-IsoPs 
among men in the highest quartile of serum selenium(8), and a small (forty intensive care 
patients) short term (three day) clinical intervention study found no effect of high dose 
selenium (474, 316, or 158 μg/day intravenous selenium selenite) on plasma F2-IsoPs(24). 
In contrast, a small randomized study in eighty-one Australian men with low baseline 
selenium (mean 122 μg/L) found no effect of selenium-fortified wheat biscuits (wheat bio-
fortified with selenium or wheat process fortified with selenomethionine, compared to 
normal wheat) on plasma F2-IsoPs, although the intervention significantly increased 
plasma selenium levels(25). Further investigation of the effect of selenium supplements on 
F2-IsoPs is needed to provide context for understanding the effect of selenium on health 
endpoints. 
In summary, past randomized trials of antioxidant nutrient effects on biological 
markers of oxidative stress report mixed results, but inferences are limited by cross-
sectional and non-randomized designs, small sample size, short duration, and exposure 
measurement error when dietary intake is used to assess nutritional status. We addressed 
this gap in knowledge using data from a large randomized study of vitamin E and selenium 
supplementation to attenuate lung function decline. Specifically, we hypothesized that 
supplementation lowers oxidative stress in cigarette smokers, and that the higher oxidative 
stress burden in this group confers greater potential to benefit from intervention.  The 
primary endpoint of the trial was rate of decline in lung function, thus we further 
hypothesized that supplementation leads to changes in F2-IsoPs that, in turn, mediate the 
protective effect of supplementation on lung function. 15
 Methods  
Study Population  
The Selenium and Vitamin E Cancer Prevention Trial (SELECT), a prostate cancer 
primary prevention trial, randomized 35,433 male participants ages fifty and older at 428 
study sites in North America to four arms: 400 IU/day α-tocopherol  (all rac-α-tocopheryl 
acetate, hereafter referred to as vitamin E) plus selenium placebo; vitamin E placebo plus 
200 µg/day selenomethionine (L-selenomethionine, hereafter referred to as selenium); 
both active supplements; or, vitamin E placebo plus selenium placebo(26). The Respiratory 
Ancillary Study (RAS) to SELECT investigated the effect of intervention on rate of decline in 
lung function in 2,920 SELECT men; cigarette smokers were preferentially studied in the 
RAS given their higher risk of steeper lung function decline(27). A urine sample at thirty-
six months on study was obtained from a subset of participants, focusing primarily on 
cigarette smokers without COPD (n=312), although a few urine samples from never 
smokers without COPD (n=32) were collected and assayed for reference values. Urine 
samples from men with a self-report of physician-diagnosed COPD at study baseline 
(n=107) were also collected to explore the effect of intervention in men with prevalent lung 
disease.  
Measurements 
ELISA Measurement of Urine F2-isoprostanes 
F2-IsoPs were assayed in prepared urine samples using a competitive enzyme 
linked immunoassay (ELISA) kit from Cayman Chemicals (Ann Arbor, MI), following 
manufacturer instructions (supplemental methods). The between-run precision for a set of 16
control samples assayed over six months was estimated by the coefficient of variation, 
which was 18.7%. 
Urine Creatinine 
Creatinine was measured in urine samples using an ATAC 8000 (Vital Diagnostics, 
Lincoln, RI) and, later, a Siemens (Deerfield, IL) Dimension Xpand Plus according to the 
manufacturers’ recommended methods. The published coefficients of variation for the 
Xpand are 2.5% and 4.2% for within- and between-run precision, respectively. Creatinine 
values from both devices were in excellent agreement, with an average difference of 2.3%. 
Lung Function  
 Spirometry was conducted following the American Thoracic Society (ATS) 
guidelines(28). All pulmonary function measurements were carried out using a handheld 
electronic spirometer (EasyOne, ndd Medizintechnik, MA); pulmonary function testing was 
performed about once per year on each participant over at least three years. Lung 
parameters of interest included forced expiratory volume in the first second (FEV1), and 
forced expiratory flow between 25 and 75 percent of the forced vital capacity (FEF25-75). All 
pulmonary function test data were reviewed weekly, and identification of measurement 
problems triggered immediate remedial action.  Only FEV1 measurements with high 
reliability (repeated measurements < 150 mL apart, the current ATS standard(28)) 
contributed to the models.  Rate of decline estimates were calculated for participants 
whose repeated lung function measurements were > 24 months apart (first to last test); 
only the first lung function measurement was used for participants not meeting this 
criterion.  
Statistical Methods  17
All analyses were carried out in SAS, version 9.3 (SAS Institute, Cary, NC). Age, 
height, smoking dose, F2-IsoPs, and lung function were continuous variables, and smoking 
status, race/ethnicity, and treatment arm were categorical variables. The main analyses 
were intent-to-treat, preserving randomization to reduce confounding bias. One participant 
with an F2-IsoP value well out of range, and of questionable validity, was excluded from all 
analyses. Natural log (ln) transformation was used to normalize the distribution of F2-
IsoPs. 
Generalized linear regression models estimated the effect of intervention on F2-
IsoPs; robust regression models were used to understand the influence of extreme, but 
valid, F2-IsoP values. Given the similarity of vitamin E effects in the vitamin E only and 
vitamin E plus selenium arms, further analyses considered the effect of any vitamin E, 
combining the two groups. Hierarchical linear regression models (mixed models) 
estimated the effect of intervention on repeated measurements of lung function, and in 
these models, mediation by F2-IsoPs was tested. In a sensitivity analysis, which was an as-
treated analysis, the sample was limited to men adherent to study supplement at the visit 
closest to the urine collection date; adherence was defined as taking at least eighty percent 
of study supplement, according to pill counts. 
Different variance-covariance matrices were investigated in the full RAS pulmonary 
function dataset (2,920 men), and variance components was selected as the best matrix 
based on degrees of freedom and comparison of AIC criteria. The Kenward-Rodgers 
method for standard error and denominator degrees-of-freedom (ddfm) correction was 
selected (ddfm=kr) for computing the denominator degrees of freedom for the tests of 
fixed effects. No discernable pattern was detected in plots of studentized residuals versus 18
predicted values, and there was no difference in residuals by treatment arm. In a sensitivity 
analysis including outlying observations, there was no difference in parameter estimates 
compared to those from the edited dataset, which excluded outliers. Refer to the Appendix 
for further details. 
 
Results  
At study baseline, participant characteristics in cigarette smokers with urine 
samples and lung function measurements were evenly distributed by treatment arm (Table 
1). Approximately 50% of men were African American, and the mean age overall was 64 
years. F2-IsoP values were highly variable in smokers (27-2218 pg/mg creatinine) and in 
men with COPD (52-1875 pg/mg creatinine, Supplemental Table 1). Unadjusted F2-IsoPs at 
thirty-six months on supplement differed by arm; in both smokers and men with COPD, 
men in the vitamin E arms had lower mean F2-IsoP values. Average nutrient levels of 
vitamin E (α-tocopherol) and selenium at baseline were 22.1 µmol/L (SD 9.8) and 170.7 
ng/mL (SD 27.7), respectively (data not shown; no difference by arm). 
Given that F2-IsoPs were assayed in samples collected after thirty-six months on 
supplement (thus no baseline F2-IsoP data are available), and assuming an intervention 
effect on the biomarker, the relation of participant characteristics to urine F2-IsoPs was 
considered only for the placebo arm (Table 2). Current smokers and men with COPD (Table 
2 and Supplemental Table 3, respectively) had similar urine F2-IsoP concentrations, and, in 
comparison, values were 50% lower among disease-free never smokers (mean 222 pg/mg 
creatinine; Supplemental Table 2). Current smokers with COPD had the highest 
concentration of urine F2-IsoPs, with a mean concentration twice as high as disease-free 19
current smokers (809 vs. 461 pg/mg creatinine, Supplemental Table 3 and Table 2, 
respectively). Among current smokers in the placebo arm, African Americans had 30% 
higher urine F2-IsoPs compared to other race/ethnicities (mostly Caucasian). Increased 
smoking dose was associated with elevated F2-IsoPs, and concentrations also increased 
with age; the trend with age was best reflected by the median given the influence of 
extreme observations on the mean in the younger age categories. Contrary to expectation, 
higher body mass index (BMI), an indicator of adiposity, was associated with lower average 
and median F2-IsoPs.  
Vitamin E and Urine F2-IsoPs 
In cigarette smokers, treatment with vitamin E alone decreased urine F2-IsoPs by 21% 
(p=0.0231); the effect was attenuated in the combination arm (vitamin E plus selenium), 
with a 9% reduction, and was not statistically significant (Table 3). There was no 
statistically significant effect of selenium on F2-IsoPs; the direction of the effect was 
unexpectedly positive, indicating an increase in oxidative stress with supplementation. In a 
sensitivity analysis, limiting the sample to men adherent to study supplement (data not 
shown), the magnitude of the vitamin E effect increased; vitamin E was associated with a 
27% reduction in F2-IsoPs (p=0.0115). The effect of selenium, alone and in combination 
with vitamin E, was unchanged in the sensitivity analysis, and neither effect was 
statistically significant.  
When both vitamin E arms were combined into a single ‘any’ vitamin E group (alone or 
in combination with selenium), the intervention reduced the biomarker by 16% compared 
to the placebo group (β = -0.160, p=0.0669). In the sensitivity analysis including only 
adherent men, the magnitude of effect increased, and any vitamin E reduced urine F2-IsoPs 20
by 19% compared to placebo (β=-0.186, p=0.872, data not shown). Adjusting for smoking 
dose had little or no effect on the regression coefficients for treatment, but smoking dose 
was a significant independent predictor of urine F2-IsoPs (β=0.004, p=0.0351, in model 
testing effect of treatment). Furthermore, there was no evidence of an interaction between 
smoking dose and treatment (Type III P-value=0.6822) in relation to effects on F2-IsoPs.  
F2-IsoPs and FEV1 Rate of Decline  
 The effect of supplementation on a functional outcome, lung function decline, which 
is reported elsewhere for the RAS sample(27), was also investigated in this smoking 
subsample of the RAS (Table 4). Models with and without adjusting for smoking dose were 
considered to address over-control, given smoking leads to higher F2-IsoPs, but effects 
were similar thus models unadjusted for smoking dose are described below.  
In current smokers the annual rate of decline in FEV1 was 38 mL/year. Vitamin E 
alone attenuated the rate of decline (p=0.1555). The combination of vitamin E plus 
selenium also attenuated rate of decline in FEV1, but to a lesser extent (Type III p-value for 
treatment categorical variable = 0.4470). While higher F2-IsoPs were associated with 
lower cross-sectional FEV1 (p=0.0679), there was no association of F2-IsoPs with FEV1 rate 
of decline (p=0.7922). In the sensitivity analysis limited to participants adherent to study 
supplement, vitamin E effects on lung function decline were similar (reduced decline by 20 
mL/yr, p=0.2897; data not shown).  
While vitamin E reduced F2-IsoPs and attenuated rate of decline in FEV1, there was 
no evidence that the effect of vitamin E on rate of decline was mediated by F2-IsoPs; thus, 
in models estimating the effect of treatment on lung function decline, the coefficient for the 
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time by treatment interaction term (the effect of treatment on rate of decline) did not 
change appreciably when F2-IsoPs were added to the model. 
In the small subgroup of men with COPD (n=107), a similar set of analyses was 
conducted (Supplemental Tables 1, 3-8). While the small sample size precludes definitive 
conclusions, results were consistent with an effect of vitamin E to lower oxidative stress, as 
reflected by urine F2-IsoPs. In contrast to the findings in current smokers, a similar effect 
of half the magnitude was observed for selenium supplementation, and the greatest 
reduction in oxidative stress was in the combined arm (F2-IsoPs lowered by 21%; 
p=0.2381).   
A second outcome, FEF25-75, which is a marker of small airways function, was also 
considered in analyses of current smokers (Supplemental Table 7), and the findings were 
similar to the FEV1 endpoint in that there was no evidence that F2-IsoPs mediated an effect 
of treatment on FEF25-75. 
 
Discussion  
This large, randomized intervention study permits a strong test of the hypothesis 
that antioxidant nutrients lower systemic oxidative stress as reflected by the F2-IsoP 
biomarker. Previous studies reporting mixed effects of vitamin E on F2-IsoPs were limited 
by sample size, study duration, self-reported dietary intake, and non-randomized designs. 
The randomized controlled trial reported herein provides definitive evidence that 
supplemental long-term synthetic α-tocopherol lowers oxidative stress, as reflected by the 
urine F2-IsoP biological marker. While higher F2-IsoPs were associated with a lower FEV1, 
there was no evidence of an association with rate of decline in FEV1. In this study of current 22
smokers, while treatment with vitamin E attenuated rate of decline in FEV1, there was no 
evidence that this effect was mediated by lowering systemic F2-IsoPs.   
  No prior randomized controlled trials investigate the effects of long-term 
antioxidant supplementation, including vitamin E and selenium, on F2-IsoPs. Furthermore, 
no prior studies investigate the relation between lowering an oxidative stress biomarker 
and change in a functional outcome such as lung function. A recent observational study 
reported that urine F2-IsoPs were independently associated with mortality in patients with 
pulmonary arterial hypertension, underscoring the potential importance and utility of this 
biomarker in predicting lung health outcomes(29). Previous randomized controlled trials 
of antioxidant supplements and respiratory disease report mixed results(30-33), with most 
reporting no effect of vitamin E on lung disease outcomes. The current study is unique 
given the focus on prevention of lung function decline rather than disease, and the 
objective measurements collected, namely lung function and F2-IsoPs, are not subject to 
reporting bias as are the self-reported disease outcomes used in prior studies.   
While there was no evidence that F2-IsoPs mediated the effect of vitamin E on rate 
of decline in FEV1, the lack of mediation may be due to design issues. Although urine F2-
IsoPs are a well-accepted biomarker of systemic oxidative stress that reflects whole-body 
processes, a lung-specific biomarker may be needed to identify mediation of effects on lung 
function. Furthermore, a single measure of F2-IsoPs at thirty-six months on study may not 
be indicative of usual, long-term values; change in F2-IsoPs from baseline to 36 months on 
study might have been more informative. Finally, another possibility is that vitamin E 
effects on lung function are mediated through pathways other than oxidative stress. 
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The vitamin E plus selenium effects are lower than the effect of vitamin E alone, for 
both the oxidative stress and the lung function endpoints. While there is no known 
mechanism through which selenium would reduce the antioxidant effects of vitamin E, and 
although selenium is a key component in antioxidant enzymes, effects in a selenium-replete 
sample such as the RAS(34) are less well understood. Selenium may have pro-oxidant 
activity at higher doses, but selenomethionine, the form of selenium studied herein, is not 
thought to have such pro-oxidant activity(35, 36). In this sample of cigarette smokers the 
effect of selenium alone was not statistically significant, but coefficients were consistent 
with an effect of selenium to increase urine F2-IsoPs in comparison to placebo, and the F2-
IsoP-lowering effects were attenuated in the combination arm compared to the vitamin E 
alone arm. Thus, a pro-oxidant effect of selenium in this study cannot be ruled out.  
 The choice of urine F2-IsoPs was deliberate, as this biomarker is more stable than 
other biomarkers of oxidative stress and it reflects free radical lipid peroxidation(3). There 
is minimal diurnal variation in F2-IsoP levels(37), and therefore spot urine collections, as 
used herein, sufficiently capture a representative daily F2-IsoP value. While other studies 
measure plasma F2-IsoPs, urine F2-IsoPs are proposed to more accurately reflect in vivo 
lipid peroxidation since the higher lipid content in plasma results in ex vivo production of 
F2-IsoPs. Thus, plasma samples require immediate and rigorous processing for accurate 
assessment of F2-IsoP levels, whereas urine samples can be stored for long periods of time, 
and measurement is less affected by variation in sample handling(14).  Additionally, 
plasma F2-IsoPs, due to rapid clearance, only reflect a brief period of time(38), but urine 
F2-IsoPs are a more time-integrated marker. There is some disagreement on whether 
ELISA is less accurate than gas chromatography/mass spectroscopy (GC/MS) for F2-IsoP 24
measurement(39), however our key comparisons require the correct rank ordering of 
samples, not detection of the most accurate actual value, minimizing any concerns about 
the use of ELISA.   
 A few small vitamin E intervention studies reported lowering of oxidative stress 
biomarkers, other than urine F2-IsoPs, in individuals with COPD(40, 41). As reviewed by 
Tsigliani et al, prior studies of antioxidant supplementation, including vitamin E, in COPD 
patients did not detect an effect of supplements on lung function(42). However, most prior 
studies were of short duration, small sample size, measured lower quality biomarkers, and 
did not assess rate of decline. Only one longitudinal study of COPD patients investigated the 
relation of systemic biomarkers to rate of decline in FEV1, but F2-IsoPs were not 
investigated and none of the measured biomarkers predicted rate of decline(43). Due to 
limited numbers (n=105), our analyses of participants with COPD were exploratory.  
Smokers with COPD had less steep decline compared to never smokers with COPD, 
although at baseline men with COPD had much lower FEV1 compared to COPD-free 
individuals. Vestbo et al report a “burn out” in rate of decline in COPD patients(43), which 
may explain the trends seen in this study. In participants with COPD, although no effect of 
supplement on rate of decline in lung function was observed, all supplements led to 
lowering of urine F2-IsoPs, and, in contrast to findings in disease-free smokers, the greatest 
reduction was in the combination arm.  
While both nutrients studied have clear antioxidant functions, selenium and vitamin 
E may, under certain circumstances, act as pro-oxidants(35, 36, 44). When α-tocopherol 
reacts with reactive oxygen species in its antioxidant capacity, α-tocopherol radicals are 
formed, which can induce lipid peroxidation if the radicals are not reduced by co-25
antioxidants such as vitamin C(44). Thus, associations between vitamin E and health 
endpoints may differ between observational studies, where diets high in vitamin E are 
likely to be similarly high in co-antioxidant nutrients, and intervention studies, particularly 
if the intervention does not include a co-antioxidant capable of reducing the vitamin E 
radical. The dual nature of the intervention nutrients, which requires careful consideration 
of context, including participant nutriture prior to supplementation and/or the dose and 
form of supplement, deserves further study. 
 This study provides strong evidence that vitamin E lowers a urine biomarker of 
systemic oxidative stress in cigarette smokers. Given reports of potentially harmful effects 
of vitamin E supplementation(45, 46), the possible benefits of supplementation must be 
carefully considered in the context of balancing risks and benefits. To our knowledge, this 
is the largest epidemiologic study of the effects of vitamin E on an oxidative stress 
biomarker. The consistency of effects on F2-IsoPs in both vitamin E arms (E alone and E 
plus Se), and the increased effect magnitude in sensitivity analyses limited to adherent 
participants support a true effect of vitamin E to lower systemic oxidative stress in 
cigarette smokers.  
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Table 1. Characteristics of RAS Participants, by Study Arm, For Current Smoker Men 
Providing Urine Sample at 36 Months of Supplementationa 
 
a RAS, Respiratory Ancillary to SELECT; SELECT, The Selenium and Vitamin E Cancer 
Prevention Trial. Current smokers include only men without Chronic Obstructive 
Pulmonary Disease (COPD). Urine samples collected from 9/2004 to 10/2008. Values in 
table are mean ± standard deviation or number (%) of participants. Values for weight, race, 
height, BMI are study baseline; all other variables describe participant status up to of date 
of urine collection 
b Time on study at urine collection. By protocol, urine collected at 36 months on study; 
dates of urine collection ranged from 24-76 months on study.  
cAt study baseline 
d Smoking dose for current smokers only  
e Median (Range)  
 
 
  
Variable: 
Placebo Vitamin E Selenium 
Vitamin E plus 
Selenium 
Number  81 82 66 83 
Age, years 62.9 ± 5.8 62.9 ± 6.3 63.6 ± 7.0 63.0 ± 5.7 
Time on Study, 
monthsb 
38.1  ± 6.7 37.9  ± 5.4 37.4 ± 5.1 38.8 ± 7.6 
Body Mass Index 
(BMI), kg/m2c 
26.8 ± 4.4 27.5 ± 4.6 27.2 ± 3.7 27.2 ± 4.4 
Height, cmc 177.6 ± 7.6 176.5 ± 7.6 175.6 ± 7.9 175.4 ± 7.3 
Weight, kgc 84.9 ± 16.3 85.5  ± 14.1 84.6  ± 13.8 83.6 ± 14.7 
Race 
African   
American 
43 (53) 38 (46) 42 (64) 40 (48) 
Caucasian/ 
Other 
38 (47) 44 (54) 24 (36) 43 (52) 
Cigarettes Smoked Per Dayd 
<5/day 15 (19) 18 (22) 15 (23) 19 (23) 
≥5/day 66 (81) 64 (78) 51 (77) 64 (77) 
Urine 8-iso-PGF-2α 
(pg/mg 
creatinine) 
461.3 ± 
355.7 
354.0 ± 
251.2 
480.1 ± 
305.4 
408.6 ± 
319.7 
347.0  
(82.0-1767.6)e 
281.3  
(55.0-1366.3) 
399.7  
(27.5-1723.3) 
343.8  
(58.4-2218.1) 
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Table 2. Urine 8-iso-PGF-2α (pg/mg creatinine) According to Demographic Characteristics 
Among Current Smokers in the Double Placebo Arm (n=81) of the RASa 
Characteristic 
Mean 
(SD) 
Median 
(Range) 
Full Sample 
461.3  
(355.7) 
347.0  
(82.0-1767.6) 
Age 
50-59  
460.2  
(345.7) 
329.4  
(90.8-1444.9) 
60-69  
477.6  
(391.7) 
348.4  
(82.0-1767.6) 
≥70  
387.0  
(183.6) 
347.0  
(129.7-677.8) 
Ethnicity/Race 
African-American  
516.5  
(413.8) 
389.5  
(129.7-1767.6) 
Caucasian/Other  
398.9  
(267.8) 
331.9  
(82.0-1291.4) 
Smoking Dose 
<5 cigarettes/day  
435.3  
(379.3) 
282.3  
(90.8-1376.5) 
≥5 cigarettes/day  
467.2  
(353.0) 
363.8  
(82.0-1767.6) 
Body Mass Index (BMI), kg/m2 
≤25 
520.7 
(404.4) 
366.2 
(98.8-1767.6) 
≥25 
418.4 
(313.4) 
334.1 
(82.0-1712.0) 
 
a RAS, Respiratory Ancillary to SELECT; SELECT, The Selenium and Vitamin E Cancer 
Prevention Trial. Current smokers include only men without Chronic Obstructive 
Pulmonary Disease (COPD).   
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Table 3. Linear Regression Estimates of the Effect of Treatment on Urine 8-iso-PGF-2α in 
Current Cigarette Smokers in the RAS to SELECTa 
 
Placebo Vitamin E Selenium 
Vitamin E plus 
Selenium 
Model-derived Estimates: 
Predictedb urine 8-
iso-PGF-2α,  pg/mg 
creatinine  
380 302 409 347 
 % change in urine 8-
iso-PGF-2αc 
Reference -21% 8% -9% 
Model Results: 
Regression 
Coefficientd 
Reference  -0.230 0.069 -0.090 
SEe - 0.101 0.107 0.101 
P-valuef - 0.0231 0.5217 0.3738 
 
a RAS, Respiratory Ancillary to SELECT; SELECT, The Selenium and Vitamin E Cancer 
Prevention Trial. Current smokers (n=312) include only men without Chronic Obstructive 
Pulmonary Disease (COPD). Least squares regression included treatment variables and 
adjusted for age and race; Type III P-value for set of treatment variables, p=0.0303 
b ln(geometric mean) 
c Percent (%) change in urine 8-iso-PGF-2α concentration; values at 36 months for each 
treatment group compared to placebo/placebo reference group 
dRegression coefficient conveys estimated difference in ln urine 8-iso-PGF-2α concentration 
for each treatment group compared to placebo 
e SE, standard error of regression coefficient 
f P-value, Wald’s test of regression coefficient 
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Table 4. Association of Lung Function (FEV1) with Urine 8-iso-PGF2α Estimated in 
Hierarchical Linear Regression Models for Current Cigarette Smokers in the RAS to 
SELECTa 
 
 Vitamin E Selenium 
Vitamin E 
plus 
Selenium 
Model-derived Estimates of Treatmentb x Time Interactionc: 
Unadjusted 
Regression 
Coefficientd 
22.4 0.2 14.4 
SEe 15.4 16.5 15.4 
P-valuef 0.1453 0.9892 0.3510 
Adjustedg,h 
Regression 
Coefficientd 
22.0 1.0 14.0 
SEe 15.5 16.7 15.4 
P-valuef 0.1555 0.9525 0.3641 
 
a FEV1, forced expiratory volume in the first second; RAS, Respiratory Ancillary to SELECT; 
SELECT, The Selenium and Vitamin E Cancer Prevention Trial. Current smokers, N=310, 
excluding cases of chronic obstructive pulmonary disease (COPD); regression models 
included treatment variables and adjusted for age and race; Type III P-value for set of 
treatment variables, unadjusted p=0.3937, adjusted p=0.4470 
b Each treatment arm is compared to placebo/placebo, the reference group; 
c Time (years), is the time variable in the mixed model; the coefficient for time conveys the 
average annual change in the lung function; the interaction of time * treatment conveys the 
effect of treatment on annual decline in lung function  
d Regression coefficient conveys estimated difference in rate of decline in lung function for 
each treatment group compared to placebo. Model included age, height, race, time (years), 
treatment, F2-IsoPs, and 2-way interaction terms between time and smoking status, 
treatment, and F2-IsoPs. Urine F2-IsoPs were ln-transformed. 
eSE, standard error of regression coefficient 
 f P-value, Wald’s test of regression coefficient 
g Adjusted model accounts for F2-IsoPs and interaction between time and F2-IsoPs 
h lnF2-IsoPs β=-95.0 (51.9), p=0.0679; lnF2-IsoPs x time β=-2.3 (8.7), p=0.7922; mean rate 
of decline -37.5 mL/yr 
  
30
References  
1. Barnes PJ. Reactive oxygen species and airway inflammation. Free Radical Biology & 
Medicine 1990;9:235-243.  
2. Macnee W. Oxidants/Antioxidants and COPD. Chest 2000;117:303S-17S.  
3. Kadiiska MB, Gladen BC, Baird DD, et al. Biomarkers of Oxidative Stress Study II: Are 
oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radical 
Biology and Medicine 2005;38:698-710.  
4. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of 
prostaglandin F2-like compounds are produced in vivo in humans by a non-
cyclooxygenase, free radical-catalyzed mechanism. Proceedings of the National Academy of 
Sciences 1990;87:9383-7.  
5. Kadiiska MB, Gladen BC, Baird DD, et al. Biomarkers of oxidative stress study: are plasma 
antioxidants markers of CCl4 poisoning? Free Radical Biology and Medicine 2000;28:838-
45.  
6. Basu S. F2-isoprostanes in human health and diseases: from molecular mechanisms to 
clinical implications. Antioxidants & Redox Signaling 2008;10:1405-34.  
7. Morrow JD, Frei B, Longmire AW, et al. Increase in Circulating Products of Lipid 
Peroxidation (F2-Isoprostanes) in Smokers — Smoking as a Cause of Oxidative Damage. N 
Engl J Med 1995;332:1198-203.  
8. Helmersson J, Ärnlöv J, Vessby B, Larsson A, Alfthan G, Basu S. Serum selenium predicts 
levels of F2-isoprostanes and prostaglandin F2α in a 27 year follow-up study of Swedish 
men. Free Radical Research 2005;39:763-70.  
9. Pratico D, Basili S, Vieri M, Cordova C, Violi F, Fitzgerald GA. Chronic Obstructive 
Pulmonary Disease Is Associated with an Increase in Urinary Levels of Isoprostane F2alpha 
-III, an Index of Oxidant Stress. Am J Respir Crit Care Med 1998;158:1709-14.  
10. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-Isoprostane as an In Vivo 
Biomarker of Lung Oxidative Stress in Patients with COPD and Healthy Smokers. Am J 
Respir Crit Care Med 2000;162:1175-7.  
11. Basu S, Helmersson J, Jarosinska D, Sällsten G, Mazzolai B, Barregård L. Regulatory 
factors of basal F2-isoprostane formation: Population, age, gender and smoking habits in 
humans. Free Radic Res 2009;43:85-91.  
12. Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane in 
exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003;58:294-8.  31
13. Schnabel RB, Lunetta KL, Larson MG, et al. The Relation of Genetic and Environmental 
Factors to Systemic Inflammatory Biomarker Concentrations. Circulation: Cardiovascular 
Genetics 2009;2:229-37.  
14. Mayne ST. Antioxidant Nutrients and Chronic Disease: Use of Biomarkers of Exposure 
and Oxidative Stress Status in Epidemiologic Research. The Journal of Nutrition 
2003;133:933S-40S.  
15. Hu G, Cassano PA. Antioxidant Nutrients and Pulmonary Function: The Third National 
Health and Nutrition Examination Survey (NHANES III). American Journal of Epidemiology 
2000;151:975-81.  
16. Grievink L, Smit HA, Ocké MC, van ‘t Veer P, Kromhout D. Dietary intake of antioxidant 
(pro)-vitamins, respiratory symptoms and pulmonary function: the MORGEN study. Thorax 
1998;53:166-71.  
17. Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of Oxidant Stress In Vivo in 
Chronic Cigarette Smokers. Circulation 1996;94:19-25.  
18. Patrignani P, Panara MR, Tacconelli S, et al. Effects of Vitamin E Supplementation on F2-
Isoprostane and Thromboxane Biosynthesis in Healthy Cigarette Smokers. Circulation 
2000;102:539-45.  
19. Burton GW, Traber MG, Acuff RV, et al. Human plasma and tissue alpha-tocopherol 
concentrations in response to supplementation with deuterated natural and synthetic 
vitamin E. The American Journal of Clinical Nutrition 1998;67:669-84.  
20. Sutherland WHF, Manning PJ, Walker RJ, de Jong SA, Ryalls AR, Berry EA. Vitamin E 
supplementation and plasma 8-isoprostane and adiponectin in overweight subjects. 
Obesity 2007;15:386-91.  
21. Block G, Jensen CD, Morrow JD, et al. The effect of vitamins C and E on biomarkers of 
oxidative stress depends on baseline level. Free Radical Biology and Medicine 
2008;45:377-84.  
22. Brenneisen P, Steinbrenner H, Sies H. Selenium, oxidative stress, and health aspects. 
Mol Aspects Med 2005;26:256-67.  
23. Rayman MP. Selenium and human health. The Lancet 379:1256-68.  
24. Mishra V, Baines M, Perry SE, et al. Effect of selenium supplementation on biochemical 
markers and outcome in critically ill patients. Clinical Nutrition 2007;26:41-50.  
25. Wu J, Salisbury C, Graham R, Lyons G, Fenech M. Increased consumption of wheat 
biofortified with selenium does not modify biomarkers of cancer risk, oxidative stress, or 
immune function in healthy Australian males. Environ Mol Mutagen 2009;50:489-501.  32
26. Lippman SM, Goodman PJ, Klein EA, et al. Designing the Selenium and Vitamin E Cancer 
Prevention Trial (SELECT) J Natl Cancer Inst 2005;97:94-102.  
27. Cassano PA, Guertin KA, Kristal AR, et al. A Randomized Controlled Trial of Vitamin E 
and Selenium on Rate of Decline in Lung Function; in preparation.  
28. American Thoracic Society. Standardisation of spirometry. European Respiratory 
Journal 2005;26:319-38.  
29. Cracowski J, Degano B, Chabot F, et al. Independent Association of Urinary F2-
Isoprostanes With Survival in Pulmonary Arterial Hypertension. Chest 2012;142:869-76.  
30. Agler AH, Kurth T, Gaziano JM, Buring JE, Cassano PA. Randomised vitamin E 
supplementation and risk of chronic lung disease in the Women's Health Study. Thorax 
2011;66:320-5.  
31. Cassano PA, Arnold KB, Guertin KA, et al. Effect Of Vitamin E And Selenium On Incidence 
Of Physician-Diagnosed COPD: The Selenium And Vitamin E Cancer Prevention Trial 
(SELECT); in preparation.  
32. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of 
antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised 
placebo-controlled trial. Lancet 2002;360:23.  
33. Rautalahti M, Virtamo J, Haukka J, et al. The Effect of Alpha-Tocopherol and Beta-
Carotene Supplementation on COPD Symptoms. Am J Respir Crit Care Med 1997;156:1447-
52.  
34. Lippman SM, Klein EA, Lippman SM, et al. Effect of Selenium and Vitamin E on Risk of 
Prostate Cancer and Other Cancers: The Selenium and Vitamin E Cancer Prevention Trial 
(SELECT). JAMA 2009;301:39-51.  
35. Spallholz JE. On the nature of selenium toxicity and carcinostatic activity. Free Radical 
Biology and Medicine 1994;17:45-64.  
36. Stewart MS, Spallholz JE, Neldner KH, Pence BC. Selenium compounds have disparate 
abilities to impose oxidative stress and induce apoptosis. Free Radical Biology and 
Medicine 1999;26:42-8.  
37. Helmersson H, Basu S. F2-Isoprostane excretion rate and diurnal variation in human 
urine. Prostaglandins, Leukotrienes and Essential Fatty Acids 1999;61:203-5.  
38. Nourooz-Zadeh J. Key issues in F2-isoprostane analysis. Biochem Soc Trans 
2008;36:1060-5.  
33
39. Il'yasova D, Morrow JD, Ivanova A, Wagenknecht LE. Epidemiological marker for 
oxidant status: comparison of the ELISA and the gas chromatography/mass spectrometry 
assay for urine 2,3-dinor-5,6-dihydro-15-F2t-isoprostane. Ann Epidemiol 2004;14:793-7.  
40. Agacdiken A, Basyigit I, Özden M, et al. The effects of antioxidants on exercise-induced 
lipid peroxidation in patients with COPD. Respirology 2004;9:38-42.  
41. Daga MK, Chhabra R, Sharma B, Mishra TK. Effects of Exogenous Vitamin E 
Supplementation on the Levels of Oxidants and Antioxidants in Chronic Obstructive 
Pulmonary Disease. Journal of Bioscience 2003;28:7-11.  
42. Tsiligianni IG, van der Molen T. A systematic review of the role of vitamin insufficiencies 
and supplementation in COPD. Respiratory Research 2010;11:171.  
43. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in FEV1 over time in COPD. New 
England Journal of Medicine 2011;365:1184-92.  
44. Rietjens IM, Boersma MG, Haan L, et al. The pro-oxidant chemistry of the natural 
antioxidants vitamin C, vitamin E, carotenoids and flavonoids. Environ Toxicol Pharmacol 
2002;11:321-33.  
45. Klein E, Thompson I, Tangen C, et al. Vitamin E and the risk of prostate cancer: The 
selenium and vitamin E cancer prevention trial (SELECT). The Journal of the American 
Medical Association 2011;306:1549-56.  
46. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of 
vitamin E and beta carotene on the incidence of lung cancer and other cancers in male 
smokers. N Engl J Med 1994;330:1029-35.  
 
34
ONLINE SUPPLEMENTAL MATERIALS 
 
Supplemental Methods: 
Measurements 
Purification of urine samples 
Urine specimens were collected at in-person SELECT visits after thirty-six months 
on study supplement using a “clean catch” method into sterile urine collection containers. 
Specimens were sealed and shipped overnight in an insulated container with ice to Cornell 
University. A single technician performed all F2-IsoP and creatinine assays. Upon arrival at 
Cornell, urine samples were pipetted into cryovials in 2 mL aliquots then immediately 
frozen at -80oC. Once all specimens were collected, samples were thawed at room 
temperature, centrifuged to remove particulates, then 1 mL aliquots were added to 
microcentrifuge tubes. Addition of 200 µL of sorbent to the microcentrifuge tubes was 
followed by gentle mixing for 45 minutes. The tubes were then centrifuged to sediment out 
the sorbent and the supernatant was removed and disposed of. The remaining sorbent was 
washed with 1 mL Nanopure water then centrifuged with removal and disposal of the 
supernatant. The washing procedure was repeated. The washed sorbent was then 
resuspended in 0.5 mL Eicosanoid Affinity Column Elution Buffer (Fisher Scientific) and 
briefly vortexed. The sample was then centrifuged and the elution buffer was removed and 
saved. The resuspension was repeated and the elution buffer washes were all combined 
and dried down overnight on a speed vacuum. Dried samples were then dissolved in 1 mL 
of EIA buffer (Cayman Chemicals). 
ELISA measurement of F2-isoprostanes 35
F2-IsoPs were assayed according to manufacture directions. Dilute EIA and wash 
buffers were prepared with Nanopure water. Eight standard samples were prepared by 
mixing with EIA buffer with the standard using serial dilutions. The 500 dtn tracer was 
reconstituted with 30 mL of EIA buffer and the 500 dtn antiserum was reconstituted with 
30 mL of EIA buffer. Plate set up was performed per the Cayman Chemical suggested 
method. After all standards, samples, tracers and antiserum aliquots were added to the 
plate, the plate was covered and incubated for 18 hours at room temperature. The plate 
was developed by reconstituteing 250 dtn of Ellman’s Reagent with 50 mL of Nanopure 
water. The plate was washed 5 times with wash buffer solution. To each well of the plate, 
200 µL of Ellman’s Reagent was added and 5 µL of tracer was added to total activity wells. 
The plate was then covered and the plates were developed on a shaker in the dark. The 
plate was read at 405 nm wavelength after 60 minutes and 90 minutes of development. 
 
  
36
Supplemental Table 1 Characteristics of RAS Participants, by Study Arm, For Men with 
COPD Providing Urine Sample at 36 Months of Supplementationa 
 
 
a RAS, Respiratory Ancillary to SELECT; SELECT, The Selenium and Vitamin E Cancer 
Prevention Trial; COPD, Chronic Obstructive Pulmonary Disease; samples collected from 
9/2004 to 10/2008. Values in table are mean ± standard deviation or number (%) of 
participants. Values for weight, race, height, BMI are study baseline; all other variables 
describe participant status up to of date of urine collection 
b Time on study at urine collection. By protocol, urine collected at 36 months on study; 
dates of urine collection ranged from 35-79 months on study.  
c At study baseline 
d Smoking dose for current smokers only  
e Median (Range)  
 
 
  
Variable: 
Placebo Vitamin E Selenium 
Vitamin E + 
Selenium 
Number  23 25 31 28 
Age, years 68.9 ± 7.7 66.0 ± 7.8 64.6 ± 8.0 66.4± 7.4 
Time on Study, 
monthsb 
39.7 ± 7.7 37.2 ± 2.8 38.1  ± 7.7 36.5 ± 0.5 
Body Mass Index 
(BMI), kg/m2 c 
26.4 ± 4.8 28.9 ± 6.5 26.4 ± 4.7 27.6 ± 5.2 
Height, cmc 176.1 ± 6.9 173.7 ± 5.1 178.7± 8.2 177.7  ± 7.0 
Weight, kgc 82.1 ± 15.4 88.1 ± 19.4 85.6  ± 17.2 87.4 ± 12.7 
Race 
African 
American 
9 (39) 9 (36) 18 (58) 12 (43) 
Caucasian/ 
Other 
14 (61) 16 (64) 13 (42) 16 (57) 
Cigarette Smoking  
Never 4 (17) 4 (16) 3 (10) 1 (4) 
Former 11 (48) 12 (48) 10 (32) 11 (40) 
Current 8 (35) 9 (36) 18 (58) 16 (57) 
Cigarettes Smoked Per Dayd 
<5/day 1 (4) 1 (4) 2 (6) 0 (0) 
≥5/day 7 (30) 8 (32) 16 (51) 16 (57) 
Urine 8-iso-PGF-2α 
(pg/mg 
creatinine) 
449.5 ± 407.9  391.9 ± 445.7  442.6 ± 317.8  386.2 ± 317.8  
330.2 
(81.9-1677.9)e 
246.6  
(102.6-1874.5)e 
358.0  
(108.3-1236.9)e 
293.6  
(52.2-1434.4)e 
37
 
 
Supplemental Table 2 Characteristics of RAS Participants, by Study Arm, for Never 
Smoker Men without COPD Providing Urine Sample at 36 Months of Supplementationa 
 
a RAS, Respiratory Ancillary to SELECT; SELECT, The Selenium and Vitamin E Cancer 
Prevention Trial; COPD, Chronic Obstructive Pulmonary Disease; samples collected from 
9/2004 to 10/2008. Values in table are mean ± standard deviation or number (%) of 
participants. Values for weight, race, height, BMI are study baseline; all other variables 
describe participant status up to of date of urine collection 
b Time on study at urine collection. By protocol, urine collected at 36 months on study; 
dates of urine collection ranged from 23-79 months on study.  
cAt study baseline 
d Median (Range)  
  
Variable: 
Placebo 
 
Vitamin E 
 
Selenium 
 
Vitamin E + 
 Selenium 
 
Number  7 12 7 6 
Age, years 66.1(9.3) 64.4 (7.5) 67.8 (9.9) 61.9 (4.8) 
Time on Study, monthsb 34.6 (5.3) 44.0 (12.5) 45.1 (15.7) 38.1 (2.4) 
Body Mass Index (BMI), 
kg/m2 c 
32.1 (2.1) 29.4 (4.7) 26.6 (2.0) 26.0 (3.1) 
Height, cmc 178.0 (7.2) 172.0 (7.5) 174.4 (6.4) 175.8 (8.0) 
Weight, kgc 101.1 (10.5) 87.9 (13.8) 83 (5.8) 78.7 (9.4) 
Race 
    
African American 3 (43) 4 (33) 2 (29) 3 (50) 
Caucasian/Other 4 (57) 8 (67) 5 (71) 5 (83) 
Urine 8-iso-PGF-2α (pg/mg 
creatinine) 
221.6 (132.4) 197.1 (151.6) 217.6 (177.1) 164.3 (87.2) 
181.0  
(103.7, 469.3)d 
131.8  
(64.4, 530.8)d 
147.0  
(69.5, 591.4)d 
159.0  
(67.9, 322.6)d 
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Supplemental Table 3 Urine 8-iso-PGF-2α (pg/mg creatinine) According to Demographic 
Characteristics Among Men with COPD in the Double Placebo Arm (n=23) of the RAS to 
SELECTa  
Characteristic 
Urine 8-iso-PGF-2α 
Mean 
(SD) 
Median 
(Range) 
Full Sample 
449.5  
(407.9) 
330.2  
(81.9-1677.9) 
Age 
50-59  
450.0  
(369.9) 
450.0  
(188.4-711.6) 
60-69  
419.4  
(408.0) 
226.4  
(81.9-1249.3) 
≥70  
476.7  
(448.1) 
364.6  
(113.3-1677.9) 
Ethnicity/Race 
African-American  
369.3  
(294.2) 
196.4  
(125.8-985.0) 
Caucasian/ 
Other  
501.0 
(470.1) 
365.4 
(81.9-1677.9) 
Smoking Statusb 
Never  
166.9 
(69.9) 
150.8  
(109.3-256.4) 
Former  
299.6 
(210.2) 
247.3 
(81.9-830.0) 
Current smokers   
<5 cigarettes/day  * * 
≥5 cigarettes/day  
809.1  
(526.5) 
633.1  
(160.4-1677.9) 
Body Mass Index, kg/m2 
≤ 25 
458.1 
(370.0) 
380.0 
(81.9-1249.3) 
≥25 
440.1 
463.9 
247.3 
(113.3-1677.9) 
a RAS, Respiratory Ancillary to SELECT; SELECT, The Selenium and Vitamin E Cancer 
Prevention Trial; COPD, Chronic Obstructive Pulmonary Disease 
b Smoking dose given for current smokers only 
* < 1 participant in this category 
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Supplemental Table 4 Linear Regression Estimates of the Effect of Treatment on Urine 8-
iso-PGF-2α in Men with COPD in the RASa 
 
Placebo Vitamin E Selenium 
Vitamin E + 
Selenium 
Model-derived Estimates: 
Predicted urine 8-
iso-PGF-2α, 
pg/mg creatinineb 
324 277 302 258 
% change in urine 
8-iso-PGF-2αc 
Reference 
group 
-15% -7% -21% 
Model Results: 
Regression 
Coefficientd 
Reference 
group  
-0.156 -0.064 -0.228 
SEe - 0.195 0.189 0.192 
p-valuef - 0.4268 0.7352 0.2381 
a RAS, Respiratory Ancillary to SELECT; SELECT, The Selenium and Vitamin E Cancer 
Prevention Trial; Chronic Obstructive Pulmonary Disease (COPD) cases, N=107, includes all 
men with self-reported physician-diagnosed emphysema, chronic bronchitis and/or COPD; 
least squares regression included treatment variables and adjusted for age, race, and 
smoking status; Type III P-value for set of treatment variables, 0.6357 
b ln(geometric mean) 
c Percent (%) change in urine 8-iso-PGF-2α concentration; values at 36 months in each 
treatment group compared to placebo/placebo reference group 
d Regression coefficient conveys estimated difference in ln urine 8-iso-PGF-2α concentration 
for each treatment group compared to placebo 
e SE, standard error of regression coefficient 
f P-value, Wald’s test of regression coefficient 
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Supplemental Table 5 Linear Regression to Estimate the Effect of Treatment (vitamin E 
and combined vitamin E + selenium arms combined) on Urine 8-iso-PGF-2α in Current 
Cigarette Smokers and COPD Cases in the RAS to SELECTa 
 Placebo Any Vitamin E 
Current Cigarette Smokersb 
Model-derived Estimates: 
Predictedc urine 8-
iso-PGF-2α, pg/mg 
creatinine  
379 320 
 % change in urine 
8-iso-PGF-2αd 
Reference Group -16% 
Model Results: 
Regression 
Coefficiente 
Reference Group -0.160 
SEf - 0.087 
p-valueg - 0.0669 
COPD Casesh 
Model-derived Estimates: 
Predicted urine 8-
iso-PGF-2α, pg/mg 
creatininec 
316 255 
% change in urine 8-
iso-PGF-2αd 
Reference group -19% 
Model Results: 
Regression 
Coefficiente 
Reference group -0.198 
SEf - 0.172 
p-valueg - 0.2544 
a RAS, Respiratory Ancillary to SELECT; SELECT, The Selenium and Vitamin E Cancer 
Prevention Trial; COPD, Chronic Obstructive Pulmonary Disease 
b Current cigarette smokers, N=246, excluding COPD cases; least squares regression 
included treatment variables and adjusted for age and race 
c ln(geometric mean) 
d Percent (%) change in urine 8-iso-PGF-2α concentration; each treatment group compared 
to placebo/placebo reference group 
eRegression coefficient conveys estimated difference in ln urine 8-iso-PGF-2α concentration 
for each treatment group compared to placebo 41
f SE, standard error of regression coefficient 
 g P-value, Wald’s test of regression coefficient 
h COPD cases, N=76, includes all men with self-reported physician-diagnosed emphysema, 
chronic bronchitis and/or COPD; least squares regression included treatment variables and 
adjusted for age, race, and smoking status 
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Supplemental Table 6 Association of Lung Function (FEV1) with urine 8-iso-PGF2α 
Estimated in Hierarchical Linear Regression Models for Men with COPD in the RAS to 
SELECTa 
 
 Vitamin E Selenium 
Vitamin E + 
Selenium 
Model-derived Estimates of Treatmentb x Time Interactionc: 
Unadjusted 
Regression 
Coefficientd 2.7 7.4 -43.1 
SEe 24.6 23.3 24.9 
P-valuef 
0.9120 0.7509 0.0880 
Adjustedg,h 
Regression 
Coefficientd 9.6 9.6 -29.3 
SEe 26.6 24.6 27.1 
P-valuef 
0.7184 0.6980 0.2819 
aFEV1, forced expiratory volume in the first second; COPD, Chronic Obstructive Pulmonary 
Disease; RAS, Respiratory Ancillary to SELECT; SELECT, The Selenium and Vitamin E 
Cancer Prevention Trial;  
COPD cases, N=105, includes all men with self-reported physician-diagnosed emphysema, 
chronic bronchitis and/or COPD; regression models included treatment variables and 
adjusted for age, race, and smoking status; Type III P-value for set of treatment variables, 
unadjusted P= 0.0870, adjusted P=0.3049 
b Each treatment arm is compared to placebo/placebo, the reference group; 
c Time (years), is the time variable in the mixed model; the coefficient for time conveys the 
average annual change in the lung function; the interaction of time * treatment conveys the 
effect of treatment on annual decline in lung function  
d Regression coefficient conveys estimated difference in rate of decline in lung function for 
each treatment group compared to placebo. Model included age, height, race, smoking 
status (for COPD subset), time (years), treatment, F2-IsoPs, and 2-way interaction terms 
between time and smoking status, treatment, and F2-IsoPs. Urine F2-IsoP was ln-
transformed. 
eSE, standard error of regression coefficient 
f  P-value, Wald’s test of regression coefficient 
g Adjusted model accounts for F2-IsoPs and interaction between time and F2-IsoPs 
h lnF2-IsoPs β=-182.0 (125.6), P=0.1497; lnF2-IsoPs x time β=21.2 (14.1), P=0.1359; mean 
rate of decline in men with COPD was -182.2 mL/yr 
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Supplemental Table 7 Evidence for Mediation of Treatment Effects on FEF25-75 by Urine 8-
iso-PGF2α; Estimated in Hierarchical Linear Regression Models for Men in the Respiratory 
Ancillary Study to SELECTa 
 
 Vitamin E Selenium 
Vitamin E + 
Selenium 
Current Cigarette Smokersb 
Model-derived Estimates of Treatmentc x Time Interactiond: 
Unadjusted 
Regression 
Coefficiente 24.9 18.0 32.4 
SEf 
35.5 39.7 36.8 
P-valueg 0.4831 0.6504 0.3787 
Adjustedh,i 
Regression 
Coefficiente 36.8 11.0 42.1 
SEf 
35.8 39.8 37.0 
P-valueg 0.3037 0.7827 0.2562 
COPD Casesj 
Model-derived Estimates of Treatmentc x Time Interactiond: 
Unadjusted 
Regression 
Coefficiente -21.6 -8.0 -74.6 
SEf 54.1 49.2 52.7 
P-valueg 
0.6903 0.8718 0.1590 
Adjustedh,k 
Regression 
Coefficiente -14.1 -6.9 -62.7 
SEf 55.1 49.2 54.7 
p-valueg 0.7989 0.8885 0.2539 
a FEF25-75, forced expiratory flow rate between the 25th and 75th percentile of the forced 
vital capacity (FVC); RAS, Respiratory Ancillary to SELECT; SELECT, The Selenium and 
Vitamin E Cancer Prevention Trial; 
b Current cigarette smokers, N=302, excluding cases of chronic obstructive pulmonary 
disease (COPD); least squares regression included treatment variables and adjusted for age 
and race; Type III P-value for set of treatment variables, P=0.8370 in unadjusted model, 
P=0.6316 in adjusted model 
c Each treatment arm is compared to placebo/placebo, the reference group; 44
d Time, years is the time variable in the mixed model; the coefficient for time conveys the 
average annual change in the lung function outcome; the interaction of time * treatment 
indicates the effect of treatment on annual decline in the lung function outcome 
e Regression coefficient conveys estimated difference in rate of decline in lung function for 
each treatment group compared to placebo. Model included age, height, race, smoking 
status (for COPD subset), time (years), treatment, F2-IsoPs, and 2-way interaction terms 
between time and smoking status, treatment, and F2-IsoPs. Urine F2-IsoPs was ln-
transformed. 
f SE, standard error of regression coefficient 
 g P-value, Wald’s test of regression coefficient 
h Adjusted model further accounts for F2-IsoPs and the time by F2-IsoP interaction  
i lnF2-IsoPs β=-255.2 (93.0), P=0.0063; lnF2-IsoPs x time β=41.8 (20.1), P=0.0383; mean 
rate of decline 317.9 (122.3)mL/sec/yr  
j COPD cases, N=104, includes all men with self-reported physician-diagnosed emphysema, 
chronic bronchitis and/or COPD; least squares regression included treatment variables and 
adjusted for age, race, and smoking status; Type III P-value for set of treatment variables, 
P=0.5941 
k lnF2-IsoPs β=-186.1 (162.6), P=0.2542; lnF2-IsoPs x time β=27.6 (29.0), P=0.3438; mean 
rate of decline 247.78mL/sec/yr 
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Supplemental Table 8 Effects of Treatment on Rate of Decline in FEV1 in the RAS to 
SELECTa: Mediation of Effects by Urine 8-iso-PGF2α 
 Current Smokers (N=310) COPD cases (N=105) 
  Variable βb SE P-value βb SE P-value 
Age, years -44.70 5.23 <0.0001 -30.97 10.91 0.0055 
Height, cm 21.86 4.01 <0.0001 21.61 11.38 0.0607 
Race       
African 
American 
-390.23 65.31 <0.0001 -167.65 161.23 0.3010 
Smoking Status       
Current 
Smoker 
- - - -619.50 296.42 0.0387 
Former 
Smoker 
- - - -805.86 284.59 0.0054 
Time, yc -37.46 52.08 0.4728 -182.21 80.84 0.0257 
Time by Smoking 
Status 
      
Current 
Smoker 
- - - 26.41 30.58 0.3892 
Former 
Smoker 
- - - 42.66 28.44 0.1359 
Treatmentd       
Vitamin E -244.14 92.67 0.0087 201.06 244.03 0.4116 
Selenium -81.23 98.22 0.4087 68.74 232.20 0.7677 
Vitamin E + 
Selenium 
-191.73 91.95 0.0376 500.11 237.61 0.0374 
Time by Treatment       
Vitamin E 22.03 15.46 0.1555 9.60 26.58 0.7184 
Selenium 1.00 16.70 0.9525 9.58 24.63 0.6980 
Vitamin E + 
Selenium 
14.02 15.42 0.3641 -29.32 27.14 0.2819 
8-iso-PGF2αe -94.96 51.88 0.0679 -182.03 125.55 0.1497 
Time by 8-iso-
PGF2αd,e 
-2.29 8.69 0.7922 21.18 14.12 0.1359 
 
a RAS, Respiratory Ancillary to SELECT; SELECT, The Selenium and Vitamin E Cancer 
Prevention Trial; COPD, Chronic Obstructive Pulmonary Disease 
b β is the regression coefficient from hierarchical linear regression models, adjusted for all 
variables shown in table; 
c Time, years is the time variable in the mixed model; the coefficient for time conveys the 
average annual change in the lung function outcome; the interaction of time * treatment 
indicates the effect of treatment on annual decline in the lung function outcome 
d Each treatment arm is compared to placebo/placebo, the reference group; 
e Urine 8-iso-PGF2α was ln-transformed  46
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Abstract 
Background Vitamin E has antioxidant properties, which may promote beneficial health 
outcomes. Plasma vitamin E levels vary between individuals, but to a lesser extent within 
an individual over time, and there is greater variation in supplement users compared to 
non-users, indicating variability in response to supplemental vitamin E. Little is known 
about individual characteristics that affect the degree to which plasma concentrations 
increase in response to supplementation.  
Methods We investigated the association between participant characteristics and change 
in plasma concentration in response to vitamin E supplementation (400 mg/day all rac α-
tocopheryl acetate) over three years in participants of the Respiratory Ancillary Study 
(RAS) to the Selenium and Vitamin E Cancer Prevention Trial (SELECT).  
Results On average, supplementation increased plasma α-tocopherol and decreased 
plasma -tocopherol.  Race, however, affected the magnitude of the change in plasma 
tocopherol, for both α- and γ-tocopherol. African American men had lower baseline plasma 
α-tocopherol, and had lower increases in α-tocopherol in response to supplementation 
(about 50% lower) in comparison to European Americans (p<0.0001). All associations 
were independent of cholesterol and adjustment for other covariates.  
Conclusions Future studies should consider the magnitude of the change in plasma 
concentration in relation to the effects of supplementation on health endpoints in order to 
fully assess the effects of supplementation. The apparently lower response among African 
Americans may either indicate less possible benefit, or may indicate more immediate use of 
supplementation, thus more possible benefit. The identification of subgroups that have 
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differential responses to supplementation, such as African Americans, may assist in 
understanding intervention effects or in the development of alternate therapies.  
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Introduction 
 Vitamin E, an essential lipid-soluble nutrient, is the most abundant antioxidant 
agent in human plasma. Its primary role in the body is to maintain the integrity of cell 
membranes by eliminating free radicals and thus preventing cellular damage caused by 
reactive oxygen species (ROS)(1). Vitamin E is comprised of four tocopherols and four 
tocotrienols, which are differentiated by the structure of the chromanol head and the 
phytyl tail. The predominant form of vitamin E in the Western diet is gamma(γ)-tocopherol, 
which is primarily found in plant sources such as vegetable oils and spreads, grains, nuts, 
fruits and vegetables(1). In contrast, the most abundant form in blood is alpha(α)-
tocopherol due to preferential binding of the α form by the α-tocopherol transfer protein 
(α-TTP) in the liver(2). Oxidative stress is hypothesized to play a key role in the 
pathophysiology of chronic diseases, thus supplementation with vitamin E, a chain-
breaking antioxidant, has long been of interest as a preventive and/or a treatment(3).  
 The hypothesized beneficial effects of vitamin E on health endpoints have not been 
borne out in published clinical trials of cardiovascular and cancer endpoints(4, 5). 
However, recent studies of lung outcomes(6, 7) support a protective effect of vitamin E 
supplementation, particularly in cigarette smokers. Given that the proposed effects of 
vitamin E are mediated by transport of vitamin E through the circulation to the relevant 
target tissue, understanding inter-individual differences in change in plasma vitamin E in 
response to supplementation is important to understand the potential to benefit from 
vitamin E supplementation.  
 The National Health and Nutrition Examination Survey (NHANES III) identified 
greater variability in plasma α-tocopherol status in individuals who consume vitamin E 51
supplements compared to non-users of supplement(8), confirming inter-individual 
variability in response to supplementation. During vitamin E supplementation, the within-
individual response (where response is change in plasma concentration) is highly 
repeatable; in contrast, there is far greater variation between individuals in response to 
supplementation (9-12). Although such differences are undoubtedly affected by the form 
and dose of vitamin E supplement used, there are few studies that address the factors that 
contribute to differences between individuals in response to supplementation with vitamin 
E. A few previous studies investigated the kinetics(9, 13-17) and inter-individual variability 
of vitamin E response(11), but these studies were limited by small sample size, short 
duration, and/or failure to consider cholesterol changes during the supplemented period. 
 Alpha-tocopherol concentration in both plasma and adipose tissue is highly variable 
between individuals(18-20), and past cross-sectional studies identified several factors 
associated with plasma α-tocopherol concentration. Age was positively associated with 
plasma α-tocopherol concentration, but effect sizes were small and associations were 
attenuated in models adjusted for cholesterol(18, 19, 21-24). An increased use of 
supplements with increasing age may also explain the weak association of age with plasma 
vitamin E (8). Putative associations with age underscore the importance of accounting for 
plasma lipids since vitamin E is transported by plasma lipoproteins, and more of the 
transport molecule is associated with higher plasma vitamin E concentration (19, 23, 25).   
African Americans have lower plasma α-tocopherol concentration compared to 
European Americans (18, 18, 19, 23), but the lower prevalence of supplement use in 
African-Americans may partly explain these differences(8). On average, African Americans 
also consume lower amounts of dietary vitamin E(18), which is expected to contribute to 52
lower plasma concentrations in comparison to other race/ethnicity groups(18). The basis 
for reported differences by race/ethnicity has not been fully explored in existing literature 
(18, 18, 19, 23).  
 Plasma vitamin E concentration is lower in cigarette smokers(26, 27), which may be 
due to higher oxidative stress in smokers leading to depletion of plasma vitamin E. In 
support of this theory, among individuals dosed with labeled α-tocopherol, the α-
tocopherol disappearance rate was faster in smokers compared to non-smokers(28, 29). 
Other studies, however, report no significant differences in plasma α-tocopherol 
concentration between smokers and non-smokers(23, 25, 30-33), thus findings are mixed. 
 Body mass index (BMI), a proxy for body adiposity, is associated with lower plasma 
α-tocopherol in most studies, although not all studies adjust for plasma lipids (18, 23, 25, 
34-39). Since obese individuals may also have greater levels of oxidative stress (40), lower 
α-tocopherol levels in obese individuals may be the end result of greater utilization of α-
tocopherol to quench oxygen radicals. All prior studies are cross-sectional, which is a 
significant limitation in making a causal inference. 
 Sequence variation in genes involved in the absorption, transport, and metabolism 
of vitamin E is associated with plasma α-tocopherol concentration (41-44), and variants in 
vitamin E-related genes are proposed to account, in part, for differential effects of vitamin E 
supplementation on disease endpoints(45).  To date, a single study reported genetic 
variants were associated with plasma response to vitamin E supplementation(46), but the 
sample was comprised entirely of heavy-smoking Finnish males, limiting generalizability. 
 Understanding predictors of response to vitamin E supplementation will improve 
the interpretation of existing clinical trials, contribute to improved study designs in future 53
investigations of the role of vitamin E in health, and will help to elucidate the true effects of 
supplementation on health endpoints. Furthermore, if vitamin E does prevent and/or 
mitigate progression of some diseases, the identification of groups who do not respond to 
vitamin E will inform the development of alternative approaches. The study reported 
herein investigated the variation in plasma change in response to supplementation with 
vitamin E, using data from a large, randomized, placebo-controlled trial of vitamin E and 
selenium supplementation; the study outcome was the change in plasma α-tocopherol 
concentration from the study baseline to thirty-six months on supplementation. 
Methods 
Study Population 
 The Selenium and Vitamin E Cancer Prevention Trial (SELECT) randomized 35,433 
men aged fifty and older at 428 study sites in North America to 400 IU/day all rac-α-
tocopherol  (α-tocopheryl acetate, hereafter denoted as vitamin E) + selenium placebo, 
vitamin E placebo + 200 µg/day selenomethionine (L-selenomethionine, hereafter denoted 
as selenium), vitamin E + selenium, or, vitamin E placebo + selenium placebo. The 
Respiratory Ancillary Study (RAS) to SELECT registered a subset of 2,920 men to 
investigate the effect of treatment on lung function, and purposefully oversampled 
cigarette smokers due to their higher risk of steep decline lung function(6). All participants 
in the RAS in either vitamin E arm (n=588 vitamin E + selenium, n=578 vitamin E + 
selenium placebo) with plasma samples at both baseline and year three, were studied. In 
addition, paired plasma samples from 100 men in the placebo arm were randomly selected 
as a comparison group. 
Vitamin E Assay 54
 Blood samples were collected at SELECT baseline and year 3 on study, and stored in 
-80◦ C freezers for a maximum of nine years. Tocopherol concentrations in plasma samples 
were determined by gas chromatography-mass spectrometry (GC-MS) using a Hewlett 
Packard 6890 gas chromatograph coupled to a Hewlett Packard 6890 mass spectrometer. 
Tocopherol and free cholesterol (as silyl ethers) were quantitated against the d9-α-
tocopherol internal standard, adjusting the cholesterol values for pre-determined 
differences in detector response. While most studies assess total cholesterol, GC-MS 
assesses free unesterified cholesterol; hereafter, we use cholesterol-adjusted tocopherol to 
refer to free unesterified cholesterol adjustments. Adjustment for free cholesterol serves 
the same function as adjusting for total cholesterol, however, given the strong correlation 
between total and free cholesterol(47); additionally, the proportion of free to total 
cholesterol is considered to be relatively constant regardless of changes in total 
cholesterol(47, 48). All samples were assayed over a six-month period by a single 
technician blinded to sample identity and randomization arm. Plasma samples were 
assayed in batches of eight samples (four paired samples; baseline and year three sample 
for an individual assayed in same run) with one set of duplicates per batch. A total of 321 
duplicate pairs were assayed and the average coefficient of variation (CV), reflecting 
within-batch variation, was calculated;the CV was 9.6% for total α-tocopherol  and 1.7% for 
free cholesterol-adjusted α-tocopherol; the CV for γ-tocopherol was 13.4%. In addition, on 
each assay day a control sample was assayed in the first and last run of the day. These 
samples provided data on between-run variability; the standard deviation was 6.5 μmol/L 
and 2.1 μmol α-toc/mmol cholesterol for α-tocopherol and cholesterol-adjusted α-
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tocopherol, respectively. Coefficients of variation for all control samples were 13.9% and 
12.9%, for α-tocopherol and cholesterol-adjusted α-tocopherol, respectively.  
 In response to supplementation, plasma α -tocopherol concentration increases and 
then reaches a plateau by about day 4-5 on vitamin E supplement(12); thereafter, plasma 
concentration remains at about the same level with continued use of supplement. SELECT 
protocols required men to stop using supplements prior to randomization, but did not 
define a formal ‘washout’ period prior to randomization. Plasma concentration of α-
tocopherol in supplemented individuals is estimated to return to the un-supplemented 
value between 12 to 20 days after withdrawal of supplement(12). In SELECT, the time 
between the last use of a vitamin E supplement (pre-randomization) and study 
randomization is unknown. Including individuals whose baseline plasma vitamin E 
concentration was affected by recent use of supplements invalidates the calculation of 
change in plasma concentration in response to study intervention, thus criteria were 
developed to identify and exclude participants with strong evidence of supplement use that 
affected the baseline plasma vitamin E concentration; these criteria were independent of 
any consideration of outcome data. Meeting all four of the following criteria identified 
baseline blood samples whose plasma vitamin E was affected by recent supplement use: 
self-reported use, in the past year, of multivitamin or supplements containing > 50 IU/d of 
α-tocopherol; plasma γ-tocopherol concentration at baseline ≤2 μmol/L; >5% increase in 
plasma γ-tocopherol concentration from baseline to year 3; and presence of a supplement 
use-associated peak on GC-MS in baseline sample (prior work in an unrelated, small 
randomized trial identified this GC-MS peak only in supplement users(49). Together the 
four criteria were evidence that the gap between prior use of non-study supplement and 56
randomization was not long enough to achieve a true, un-supplemented baseline plasma 
vitamin E concentration; 78 participants were excluded for this reason.   
Statistical Analysis 
All analyses were carried out in SAS, version 9.3 (SAS Institute, Cary, NC). α-
tocopherol and γ-tocopherol levels, age, smoking dose, years smoked, and cholesterol were 
continuous variables. Race and smoking status were categorical variables. BMI was 
considered as both a categorical variable (obese, overweight compared to normal weight) 
and a continuous variable in separate models. Selenium supplementation in the 
combination treatment arm did not have a significant effect on plasma vitamin E 
concentrations; therefore, all participants taking vitamin E supplements (participants in 
the vitamin E plus placebo and in the vitamin E plus selenium arms) were combined into 
one group for analyses. Regression models estimated the association of participant 
characteristics with the change in plasma tocopherol concentration, where tocopherol 
change was calculated as the year three minus the baseline value; change in α- and γ-
tocopherol  were considered in separate models. Primary findings are based on tocopherol 
adjusted for free cholesterol at the corresponding time point, but models unadjusted for 
cholesterol were also considered to provide comparisons to published studies. One 
participant was excluded from analyses due to assay failure for the thirty-six month blood 
sample. 
Different variance-covariance matrices were investigated for the full RAS 
pulmonary function dataset, and variance components was selected as the best matrix 
choice based on comparison of AIC criteria and consideration of degrees of freedom. The 
Kenward-Rodgers method for standard error and denominator degrees-of-freedom (ddfm) 57
correction was selected (ddfm=kr) for computing the denominator degrees of freedom for 
the tests of fixed effects. No discernable pattern was detected in plots of studentized 
residuals versus predicted values, and there was no difference in residuals by treatment 
arm. In a sensitivity analysis including outlying observations, there was no difference in 
parameter estimates compared to those from the edited dataset which excluded outliers. 
Refer to the Appendix for further details. 
 
Results 
Participant Characteristics 
At baseline, participant characteristics were evenly balanced by arm (Table 1; 
placebo group in Supplemental Table 1), and the mean age was 63 years. The RAS 
selectively registered cigarette smokers, thus 16% of men were current smokers and 51% 
were former smokers. The average smoking dose in current smokers was 18.3 (SD 10.9) 
cigarettes per day. The mean years smoked was 21.1 (SD 12.9) in former smokers and 37.8 
(SD 12.7) in current smokers. African Americans comprised 23% of the sample, and 
cigarette smoking was more prevalent in this group (29% current smokers, 46% former) 
compared to European Americans (12% current, 53% former). The majority of the sample 
was overweight or obese, accounting for 46% and 34% of the sample, respectively, and the 
mean BMI was 28.9 (SD 4.7).  
At study baseline, prior to randomization, plasma concentrations of α- and γ-
tocopherol, free cholesterol, and the ratio of α- to γ-tocopherol varied (Table 1). As 
expected, the variability in plasma α-tocopherol was reduced after adjusting cholesterol, 
but a 5- to 6-fold difference from the top to bottom of the range persisted (compared to 58
about a ten-fold difference in unadjusted values). At baseline, mean α- and γ-tocopherol 
values were 19.6 and 3.6 µmol/L, respectively.  
Association of Participant Characteristics with Plasma Vitamin E  
At the study baseline, prior to supplementation, plasma tocopherol concentrations 
differed by race and smoking status (Supplemental Table 3). African Americans had lower 
α-tocopherol concentrations compared to European Americans (8.1 ± 2.9 (mean ± SD) and 
9.2 ± 3.0 µmol/mmol free cholesterol, respectively), and higher γ-tocopherol 
concentrations (1.9 ± 0.9 and  1.4 ± 0.8 µmol/mmol free cholesterol, respectively). Former 
and never smokers had similar α-tocopherol concentrations at baseline (both 9.1 
µmol/mmol free cholesterol), and current smokers had slightly lower concentrations (8.0 
µmol/mmol free cholesterol). There was little or no association of BMI with plasma α-
tocopherol concentrations at baseline (overweight 8.9, obese 9.0, normal weight 8.9 
µmol/mmol free cholesterol).  
Using the clinical definition of vitamin E deficiency (11.6 µmol/L), 4.5% of RAS 
participants were vitamin E deficient at baseline (data not shown). The prevalence of 
vitamin E deficiency varied by race such that 9% of African Americans were vitamin E 
deficient at baseline, compared to 3% of European Americans.  
Given the similarity of baseline characteristics (Table 1) between the two vitamin E 
arms (vitamin E + selenium and vitamin E + placebo arms), and in light of similar mean 
plasma α-tocopherol at year three, the two groups were combined for all further analyses. 
Hereafter, vitamin E refers to men on any vitamin E, either alone or combined with 
selenium. 
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Plasma α-tocopherol concentration increased by 40% from baseline to year three in 
participants randomized to active vitamin E supplement (Table 2); plasma concentrations 
decreased about 13% in the small sample of participants assayed in the placebo arm 
(Supplemental Table 2). Differences in cholesterol did not account for the inter-individual 
variation in change in plasma α-tocopherol concentration in response to supplementation. 
In men on vitamin E, γ-tocopherol levels decreased by about 50% (Table 2), compared to 
an increase of 11% in the placebo arm (Supplemental Table 2). The ratio of α-tocopherol to 
γ-tocopherol increased more than three-fold in the vitamin E arms (Table 2), but there was 
little or no change in the placebo arm (Supplemental Table 2). Given that vitamin E is a 
lipid-soluble vitamin, free cholesterol-adjusted results are the focus of the further analyses. 
Factors Associated with Change in Plasma Alpha-Tocopherol  
 Higher plasma concentrations of α-tocopherol at baseline were associated with less 
increase in plasma α-tocopherol in response to supplementation, and higher baseline γ-
tocopherol was associated with greater change in α-tocopherol (Tables 3, 5; p<0.0001). 
Increasing age was associated with greater change in plasma α-tocopherol in models 
unadjusted for cholesterol (data not shown), but the association was attenuated when 
adjusted for cholesterol. There was an association of BMI with change such that individuals 
with greater BMI had a greater change in plasma α-tocopherol (p=0.0479), and this 
association remained after cholesterol adjustment (Tables 3, 5).  
 Current smokers had less increase in plasma α-tocopherol concentration compared 
to never smokers (Type III P-value=0.1000), but in cholesterol-adjusted models differences 
by smoking status were attenuated (Type III P-value=0.3546), particularly after adjusting 
for other smoking variables such as smoking dose and years smoked (Tables 3, 5). The 60
baseline variables smoking dose (cigarettes per day, p=0.6125) and years smoked 
(p=0.1577) had little or no association with change in plasma α-tocopherol concentration 
in response to supplementation. 
 African Americans had lower plasma α-tocopherol concentrations, by about 1 
µmol/mmol free cholesterol, at the study baseline (Supplemental Table 3), and had less of 
an increase in plasma α-tocopherol concentration in response to supplementation in 
unadjusted models (β=-1.33, P=<0.0001, Supplemental Table 5), even after adjusting for 
lower plasma α-tocopherol concentration at baseline. In fully adjusted models, the lower 
response to supplementation in African Americans remained, and adjusting for other 
variables did not attenuate the effect (β=-1.26, P=<0.0001, Table 5). Thus, European 
Americans had both higher baseline plasma α-tocopherol concentration and a greater 
increase in plasma α-tocopherol in response to supplementation, regardless of 
consideration of potentially confounding variables (Tables 3, 5). In models investigating 
change in plasma α-tocopherol concentrations, there was no interaction between race and 
baseline plasma α-tocopherol concentration (data not shown). Considering all predictors, 
in fully adjusted models which explained 8.1% of the variability, race was the strongest 
predictor of response to supplementation, explaining 1.4% of the variability, followed by 
baseline plasma α-tocopherol concentration (β=-0.36, P<0.0001; R2 = 6.7%) and BMI 
(β=0.05, P<0.0479; R2 = 0.3%) (Table 5).  
Factors Associated with Change in Plasma Gamma-Tocopherol  
 Lower baseline plasma γ-tocopherol concentration is associated with less change in 
γ-tocopherol concentration with supplementation (Tables 4, 5; p<0.0001); 
supplementation with α-tocopherol reduces plasma γ-tocopherol levels, and the potential 61
for further γ-tocopherol-lowering may be less as baseline γ-tocopherol approaches zero. 
About 84% of participants supplemented with vitamin E experienced a decrease in plasma 
γ-tocopherol concentration, but the decrease was of greater magnitude in men with lower 
baseline plasma α-tocopherol concentration; this association persisted in models also 
adjusted for baseline γ-tocopherol concentration. 
 In comparison to European Americans, African Americans have higher baseline 
plasma γ-tocopherol concentrations (Supplemental Table 3) and less decrease in plasma γ-
tocopherol concentration (β=0.2569, p<0.0001; Supplemental Table 5) with 
supplementation (35% smaller decrease; Table 4); these differences attenuated slightly, 
but remained highly statistically significant after adjusting for covariates (Table 5). In the 
fully adjusted model which explained 56% of the variability (Table 5), baseline γ-
tocopherol (β=-0.73, P<0.0001; R2=54%) and race (β=-0.24, P<0.0001; R2= 1.4%) are 
predictive of change in γ-tocopherol.  
 
Discussion 
 Race was associated with the change in plasma tocopherol concentration in men 
supplemented with vitamin E, specifically 400 IU/d all rac-α-tocopheryl acetate. African 
American participants had a lesser increase in plasma α-tocopherol concentration in 
response to supplementation compared to European Americans, and the association was 
independent of change in cholesterol and other covariates. 
 Consistent with prior reports, African Americans had lower plasma α-tocopherol 
concentration at the study baseline, prior to supplementation, and this could not be 
explained by differential supplement use by race given baseline bloods are mainly 62
representative of un-supplemented status. Although SELECT did not have a formal 
‘washout’ period, the analysis reported herein used a set of criteria to objectively exclude 
participants whose baseline plasma samples were likely to be affected by recent 
supplement use. Lower plasma α-tocopherol concentration in African Americans may be 
explained by variation in genes involved in vitamin E absorption, transport, or metabolism; 
a recent GWAS identified SNPs associated with α-tocopherol levels after vitamin E 
supplementation(46). Alternatively, African-Americans may have lower plasma α-
tocopherol concentrations due to differences in environmental exposures and/or in 
metabolic demands that affect the disposition and utilization of systemic antioxidants.  
 Response to nutritional supplementation is expected to vary by participant 
characteristics, including baseline nutriture, thus comparison of baseline nutriture in the 
current study provides information about generalizability of these findings to the United 
States population. The median plasma α-tocopherol value in the RAS (19.6 μmol/L), was 
similar to findings reported for males in NHANES III who did not use supplements 
containing vitamin E (22.85 μmol/L) (18). The comparability between the baseline α-
tocopherol concentration in the RAS and the NHANES value from un-supplemented males 
confirms that at baseline, participants in RAS were similar to the US Population.  
Gamma-tocopherol concentrations and the ratio of α- to γ-tocopherol differed between 
the RAS and the NHANES III data (18). The baseline plasma concentration of γ-tocopherol 
in RAS participants was 3.6 µmol/L, which was about half the value in NHANES III male 
non-users of supplement (6.01 µmol/L) (18); similarly the mean α-to-γ-tocopherol ratio in 
RAS participants (~11) was about three times higher than the mean reported for male non-
users of supplements in NHANES III (3.61) (18). These discrepancies may be due to 63
differences in sample characteristics, including race distributions given that the proportion 
of African-Americans is much higher in RAS in comparison to NHANES III (separate values 
by race are not reported for NHANES III). The differences are unlikely to be attributed to 
supplement use in the RAS because we excluded participants with baseline plasma that 
may have been affected by recent supplement use. Gamma-tocopherol is understudied, and 
the biokinetics are less well characterized in comparison to α-tocopherol. Race-specific 
data are needed to reach a deeper understanding of the identified distribution differences 
in the RAS in comparison to NHANES III. 
Change in Plasma Tocopherols 
 The most striking finding is that race is a meaningful predictor of change in α-
tocopherol; specifically, African Americans had less increase in plasma concentrations in 
response to supplementation in comparison to European Americans. While plasma α-
tocopherol levels did not increase as much in African Americans, we cannot necessarily 
conclude that African Americans do not benefit from supplementation in terms of 
improved health outcomes. Less change, and lower mean concentration achieved by year 
three, may indicate that a greater proportion of the supplemental vitamin E is used, leading 
to lower circulating vitamin E; consistent with this hypothesis, previous studies reported 
decreased α-tocopherol levels in smokers(26, 27), who have greater oxidative stress 
levels(50, 51). While a greater proportion of African Americans (compared to European 
Americans) were smokers, even among never smokers African Americans had higher levels 
of a biomarker of systemic oxidative stress, urine F2-isoprostanes(52). A recently 
developed method to detect oxidative urinary α-tocopherol metabolites(53) may offer a 
useful tool to provide evidence about whether vitamin E is utilized to a greater extent in 64
African Americans. However, this method is new and requires replication and validation 
before implementation in a large-scale epidemiologic study. Given that African Americans 
have higher levels of oxidative stress(52), however, it is plausible that less change in 
response to supplements in African Americans signifies greater ‘use’ of the nutrient. 
 Smoking status was also predictive of change in plasma α-tocopherol concentration, 
and although associations were attenuated in the fully adjusted model, these models may 
be over-adjusted. Less change in plasma α-tocopherol among current smokers is consistent 
with previous findings that smokers have faster disappearance of vitamin E from their 
plasma(28, 29), and achieve lower plasma α-tocopherol levels via supplementation 
compared to non-smokers (54). While our results do not agree with a small biokinetic 
study that indicated no effect of smoking status on plasma response to vitamin E 
supplementation(55), our study is a much larger, more diverse study of long-term 
supplementation which includes African Americans, allowing for a stronger test of 
hypothesis. 
As expected, predictors of α-tocopherol were also associated with γ-tocopherol. 
While vitamin E supplementation led to a decrease in γ-tocopherol in both African 
Americans and non-African Americans, there was less change (lower decreases) in African 
Americans. This finding parallels the finding of less change (lower increases) in α-
tocopherol in response to supplementation in African Americans. Since γ-tocopherol and α-
tocopherol use the same transfer protein (α-TTP), but α-TTP has a greater affinity for α-
tocopherol(2), change in γ-tocopherol is expected to be closely linked with α-tocopherol 
levels.  
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The lower increase in plasma α-tocopherol among African Americans on vitamin E 
is a novel finding. While African Americans generally have a different lipid profile 
compared to European Americans(56, 57), including lower triglycerides and higher high 
density lipoprotein (HDL), vitamin E is expected to be proportionally distributed 
throughout all lipid particles in the plasma. While high levels of some lipids (low-density 
lipoproteins, triglycerides) are associated with increased risk of disease, we are 
considering change in plasma concentration of vitamin E independent of any disease state; 
thus, differential lipid profiles are unlikely to account for the race difference observed. 
Furthermore, the difference cannot be attributed to lower rates of supplement use among 
African Americans since all men studied herein were randomized to vitamin E supplements 
and adherence to study supplement was high, with no evidence of differential adherence by 
race/ethnicity.  
Differences in plasma response may be partly attributable to genetic variation(58, 
59); two non-synonymous SNPs in the CYP4F2 gene (rs3093105, W12G; 
rs2108622,V433M), which catalyzes the first step in the vitamin E-ω-oxidation pathway 
alter ω-hydroxylase activity, have different race-specific prevalence. The W12G variant 
results in greater ω-hydroxylase activity(59) and, given the higher prevalence of this 
variant among African Americans(60), may contribute to a lower plasma response to 
supplementation seen among African Americans in the RAS. Conversely, the V433M 
variant, more common among European Americans(60), results in less ω-hydroxylase 
activity(59) and may therefore be partly responsible for the lower response among African 
Americans. Future analyses considering genetic variants in the context of human 
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supplementation trials will better inform whether, and to what extent, racial differences in 
plasma response to supplementation are attributable to underlying genetic backgrounds. 
 There are a few limitations, which have been addressed as fully as possible. One 
limitation is the lack of a traditional ‘wash out’ period in SELECT, which may affect the 
accuracy of measuring change in plasma tocopherols. However, biochemical data provide 
ample support that at baseline, most participant tocopherol concentrations were 
unaffected by supplement use in the period preceding randomization. Participants in the 
placebo arm increased in γ-tocopherol slightly from baseline to year three (Supplemental 
Table 2), indicating that very few men used supplements at baseline, and also indicating 
that the placebo arm was truly non-supplemented at year three. Plasma assays also 
confirm that most men in the vitamin E arms at year three were adherent to the study 
supplement, since measured decreases in plasma γ-tocopherol levels (Table 2) were 
consistent with expectation for supplement users(61). Dietary data are not considered 
here, but all participants were randomized to receive the same dosage, duration, and type 
of vitamin E supplementation, and dietary vitamin E has been shown to have little impact 
on plasma α-tocopherol levels. Whether response to supplement is modified by dietary 
intake of vitamin E has not been addressed in this study. Because this study assesses 
change with two measurements of vitamin E, we are unable to estimate the trajectory of 
plasma change over time in response to supplementation. Previous studies, however, 
clearly demonstrate that plasma α-tocopherol levels increase as early as three hours post-
supplement(55), with a peak twelve hours after a single oral dose (14). Furthermore, 
plasma levels plateau by approximately day four in response to daily supplementation with 
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a consistent dose of vitamin E(14), thus by year three a steady state of plasma α-tocopherol 
is expected. 
While the present study considers a single supplemented level of vitamin E, prior 
studies demonstrated a linear increase in plasma concentration with supplemental vitamin 
E (deuterated RRR-α-tocopheryl acetate)(62), with no further increase in plasma levels 
with supplementation beyond 350 mg/d of RRR α-tocopherol(63). Daily replacement of the 
vitamin E pool is proposed to explain the plateau in plasma vitamin E at higher levels of 
supplementation(62).  
 This study has a strong design, and it addresses important gaps in knowledge by 
providing new evidence. African Americans are traditionally underrepresented in research, 
and are not included in many of the published vitamin E trials(64); as a result of intensive 
recruitment of African Americans by SELECT, African-Americans comprised 23% of the 
RAS, which allowed for explorations of the effect of race. Most previous studies are cross-
sectional, and while vitamin E is proposed to have health benefits that act by transport of 
vitamin E through the plasma to target tissues, the effect of supplementation on plasma 
levels is understudied. The GC-MS method allowed for assay of γ-tocopherol in addition to 
α-tocopherol; while α-tocopherol was previously thought to be the only tocopherol with 
biological activity, researchers are increasingly interested in the potential effects of γ-
tocopherol (65).  This is the only study to our knowledge that investigates the effect of 
long-term α-tocopherol supplementation on change in γ-tocopherol levels, and fully 
considers the influences of both tocopherols. 
 Given the need to balance the risks and benefits of supplementation with vitamin E, 
this study provides critical evidence to deepen understanding of how to identify the subset 68
of the population most likely to benefit from vitamin E supplementation. If the effect of 
supplement is hypothesized to act at the target tissue, and thus the nutrient must be 
transported to the target tissue in plasma lipoproteins, full understanding of plasma change 
in response to supplementation is needed in order to effectively target nutritional 
approaches to avoid chronic disease. These data show that African Americans have less 
response to supplementation with vitamin E. Further data are needed to determine if this 
reflects a lower functional dose or if delivered doses are being used more quickly in African 
Americans. The understanding of vitamin E metabolism is still under study, and having 
better understanding of population-level variation in metabolism is significant in adding to 
the evidence base for optimal nutrition at the individual level. 
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Table 1 Baseline Characteristics of Male Participants Randomized to Vitamin E (400 
IU/day all rac-α-tocopherol) (N=1166) in the Respiratory Ancillary Study to SELECTa 
  Treatment Arm 
 
  Vitamin E 
(n=588) 
 
Vitamin E + 
Selenium (n=578) 
Age (y) 62.6 ± 6.5b 62.8 ± 6.4 
Ethnicity [n (%)]   
European American 452 (77) 450 (78) 
African American 136 (23) 128 (22) 
Smoking Statusc [n(%)]   
Never 190 (32) 188 (33) 
Former 299 (51) 299 (52) 
Current 95 (16) 90 (16) 
Smoking Dose (cigarettes/day)d 2.7 ± 7.2 3.1 ± 8.6 
Years Smokede 16.9 ± 16.9 16.9 ± 16.8 
Body Mass Index (BMI)f [n(%)]   
Normal 94 (16) 126 (22) 
Overweight 268 (46) 277 (48) 
Obese 226 (38) 175 (30) 
BMI (kg/m2) 29.3 ± 4.7 28.5 ± 4.6 
Serum Measurementsg   
α-tocopherol 
Unadjusted  
(µmol/L) 
21.3 ± 9.1 
19.4 (6.7, 95.9) 
21.7 ± 9.3 
19.7 (8.3, 79.0) 
Free-cholesterol-
adjusted  
(µmol/mmol chol) 
8.9 ± 2.9 
8.2 (4.1, 25.8) 
9.0 ± 3.2 
8.3 (3.6, 29.8) 
γ-tocopherol 
Unadjusted values 
(µmol/L) 
3.7 ± 2.3 
3.2 (0.1, 18.2) 
3.5 ± 2.6 
2.9 (0.2, 23.4) 
Free-cholesterol-
adjusted  
(µmol/mmol chol) 
1.5 ± 0.9 
1.4 (0.1, 5.2) 
1.4 ± 0.9 
1.2 (0.1, 6.2) 
α-tocopherol/ γ-tocopherol Ratio 
10.3 ± 15.3 
5.9 (1.2, 181.2) 
11.6 ± 19.1 
6.8 (1.0, 232.8) 
Free cholesterol (mmol/L)h 
2465.5 ± 892.1 
2302.6 (937, 7764) 
2495.6 ± 886.4 
2314.6 (1034, 8626) 
Vitamin E Deficienti [n(%)] 
 
31 (5) 22 (4) 
a SELECT, The Selenium and Vitamin E Cancer Prevention Trial. 
b Mean ± SD unless otherwise indicated 
c 5 participants missing baseline smoking data (by arm: N=1 in E + Se, N=4 in E + 
placebo) 70
d 6 participants missing smoking dose (by arm: n=1 in E + Se, n=5 in E + placebo); 
never and former smokers have dose of 0). 
e 10 participants missing pack-years (by arm: n=3 in E + Se, n=7 in E + placebo); 
never smokers have value of 0 and contribute to average. 
f Obese defined as BMI ≥30; overweight defined as BMI 25-30; normal weight, BMI 
<25, is reference group. This sample did not include underweight individuals. 
g Mean ± standard deviation; Median (minimum, maximum) 
h Free cholesterol refers to unesterified lipids 
i Deficiency defined as <11.6 μmol/L α-tocopherol at baseline 
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Table 2 Plasma Tocopherol Concentration at Thirty-six Months on Supplement in Male 
Participants Randomized to Vitamin E (N=1166) in the RAS to SELECTa 
 
  Plasma Tocopherol 
at Study Baseline 
Plasma Tocopherol 
at 36 months 
Change in Plasma 
Tocopherolb 
α-tocopherol 
Unadjusted, 
µmol/L 
21.5 ± 9.2c 30.0 ± 13.9 8.5 ± 13.1 
19.5 
(6.7, 95.9)d 
27.3 
(7.5, 127.0) 
7.1 
(-54.5, 108.8) 
Adjusted, 
µmol/mmol chol 
8.9 ± 3.1 12.7 ± 4.6 3.8 ± 4.2 
8.2  
(3.6, 29.8) 
11.9 
(3.3, 47.6) 
3.2 
(-12.2, 33.9) 
γ-tocopherol 
Unadjusted, 
µmol/L 
3.6 ± 2.5 1.8 ± 1.6 -1.8 ± 2.4 
2.4 
(0.1, 23.4) 
1.3 
(0.0, 13.4) 
-1.5 
(-22.2, 9.9) 
Adjusted, 
µmol/mmol chol 
1.5 ± 0.9 0.8 ± 0.6 -0.7 ± 0.9 
1.3 
(0.1, 6.2) 
0.6 
(0.0, 4.9) 
-0.6 
(-4.6, 2.4) 
α-tocopherol/ γ-tocopherol ratio 
10.9 ±17.3 34.0 ± 36.6 23.1 ± 36.7 
6.4 
(1.0, 232.8) 
22.2 
(1.2, 290.2) 
13.1 
(-191.6, 261.7) 
a Vitamin E includes all participants on vitamin E, 400 IU/day all rac-α-tocopherol, 
which includes vitamin E + placebo and vitamin E + selenium. Placebo refers to 
participants taking both placebo pills; RAS, Respiratory Ancillary Study; SELECT, 
The Selenium and Vitamin E Cancer Prevention Trial. 
b Change in plasma concentration defined as thirty-six month value minus the 
baseline value. 
c Mean ± SD, unless otherwise indicated 
d Median; minimum, maximum in parentheses 
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Table 3 Model-based Predicted Change in Plasma α-tocopherol (µmol/mmol chol) in 
Unadjusted and Adjusted Models for Male Participants Randomized to Vitamin E (400 
IU/day all rac-α-tocopherol) (N=1166) in the RAS to SELECTa 
 
Variables in Model: Unadjusted Model Adjusted Modelb 
Baseline α-tocopherolc,d 3.82 2.58 
Baseline γ-tocopherold,e 3.82 2.04 
Race   
European American 4.12 2.86 
African American 2.79 1.66 
Agef 3.82 2.58 
Smoking Status   
Never 3.97 2.92 
Former  3.91 2.44 
Current 3.23 2.64 
Smoking Dosed,g 3.83 2.58 
Cumulative Years Smokedd,h 3.83 2.58 
Body Mass Index (BMI), 
kg/m2d,i 
3.82 2.58 
BMIj   
Normal 3.56 2.38 
Overweight 3.78 2.46 
Obese 4.03 2.79 
a Vitamin E includes all participants on vitamin E (including E + placebo and E + 
selenium); RAS, Respiratory Ancillary Study; SELECT, The Selenium and Vitamin E 
Cancer Prevention Trial. Change in plasma level defined as thirty-six month value 
minus the baseline value. All tocopherol values adjusted for free cholesterol at each 
time point. Unless otherwise noted, models predicting change in α-tocopherol adjust 
for baseline α-tocopherol level, and models predicting change in γ-tocopherol adjust 
for baseline γ-tocopherol level.  
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b Adjusted Model includes baseline α-tocopherol, smoking status, smoking dose, 
years smoked, age, race, and BMI (continuous), unless otherwise noted. For 
categorical variables, race, smoking status, and BMI category, the mean change in 
plasma α-tocopherol concentration is predicted (95% confidence interval) for each 
category. 
c Mean baseline α-tocopherol level is 8.92 µmol/mmol chol 
d Values shown for continuous variables are for predicted change in α-tocopherol 
concentration for the mean of the variable.  
e Mean baseline plasma γ-tocopherol concentration is 1.5 µmol/mmol chol 
f Mean age 62.7; 25th percentile 57.9, 75th percentile 66.7 
g Mean baseline smoking dose 2.9 cigarettes per day (for never smokers and former 
smokers, dose is zero) 
h Mean cumulative years smoked 16.87 (for never smokers, years smoked is zero) 
i Mean BMI 28.9; 25th percentile 25.7, 75th percentile 31.4 
j Obese defined as BMI ≥30; overweight defined as BMI 25-30; normal weight, BMI 
<25, serves as reference group. This sample did not include underweight 
individuals. 
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Table 4 Model-based Predicted Change in Plasma γ-tocopherol (µmol/mmol chol) in 
Unadjusted and Adjusted Models for Male Participants Randomized to Vitamin E (400 
IU/day all rac-α-tocopherol) (N=1166) in the RAS to SELECTa   
 
Variables in Model: 
Unadjusted 
Model 
Adjusted  
Modelb 
Baseline α-tocopherolc,d -0.72 -0.46 
Baseline γ-tocopherold,e -0.72 -0.47 
Race   
European American -0.78 -0.53 
African American -0.52 -0.29 
Agef -0.72 -0.47 
Smoking Status   
Never -0.74 -0.51 
Former  -0.73 -0.46 
Current -0.61 -0.48 
Smoking Dosed,g -0.72 -0.48 
Cumulative Years 
Smokedd,h 
-0.72 -0.48 
Body Mass Index (BMI), 
kg/m2d,i 
-0.72 -0.47 
BMIj   
Normal -0.73 -0.50 
Overweight -0.75 -0.50 
Obese -0.68 -0.44 
a Vitamin E includes all participants on vitamin E (including vitamin E + placebo and 
vitamin E + selenium). RAS, Respiratory Ancillary Study; SELECT, The Selenium and 
Vitamin E Cancer Prevention Trial. Change in plasma concentration defined as 
thirty-six month value minus the baseline value. All tocopherol values adjusted for 
free cholesterol at each time point. Unless otherwise noted, models predicting 
change in γ-tocopherol adjust for baseline γ-tocopherol level. Values represented for 
categorical variables are for mean predicted level (95% CI). 
b Model adjusted for all other variables, including baseline γ-tocopherol, smoking 
status, smoking dose, years smoked, age, race, and BMI. 
c Mean baseline α-tocopherol level is 8.92 µmol/mmol chol. 
d Values shown for continuous variables are for predicted change in γ-tocopherol 
concentration for the mean of the variable. 
e Mean baseline plasma γ-tocopherol concentration is 1.5 µmol/mmol chol. 
f Mean age 62.7; 25th percentile 57.9, 75th percentile 66.7 
g Mean baseline smoking dose 2.9 cigarettes per day (for never smokers and former 
smokers, dose is zero). 
h Mean cumulative years smoked 16.87 (for never smokers, years smoked is zero). 75
i Mean BMI 28.9; 25th percentile 25.7, 75th percentile 31.4. 
j Obese defined as BMI ≥30; overweight defined as BMI 25-30; normal weight, BMI 
<25, serves as reference group. This sample did not include underweight 
individuals. 
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Table 5 Regression Coefficients from Mixed Models (Adjusted Models) for Change in 
Plasma α- and γ-tocopherol (µmol/mmol chol) for Male Participants Randomized to 
Vitamin E (N=1166) in the RAS to SELECTa 
 
Variables: 
Change in Plasma -
Tocopherolb 
Change in Plasma γ-
Tocopherolc 
 P-value  P-value 
Baseline -tocopherol 
(µmol/mmol free 
cholesterol) 
-0.3639 <0.0001 - - 
Baseline γ-tocopherol  
(µmol/mmol free 
cholesterol) 
- - -0.7371 <0.0001 
Raced     
African American -1.2589 <0.0001 0.2530 <0.0001 
European American Reference - Reference - 
Age 0.0054 0.7796 0.0001 0.9850 
Smoking Dose 
(cigarettes/day) 
-0.0141 0.6125 0.0037 0.3424 
Years Smoked 0.0164 0.1577 -0.0035 0.0325 
Smoking Statuse   
Current Smokers -0.8100 0.2708 0.1439 0.1620 
Former Smokers -0.3671 0.3073 0.0675 0.1797 
Never Smokers Reference - Reference - 
Body Mass Index 
(BMI),kg/m2 
0.0508 0.0479 0.0039 0.2883 
 
a Vitamin E includes all participants on vitamin E (including vitamin E + placebo and 
vitamin E + selenium). RAS, Respiratory Ancillary to SELECT; SELECT, The Selenium 
and Vitamin E Cancer Prevention Trial. Change in plasma level defined as thirty-six 
month value minus the baseline value. All tocopherol values adjusted for free 
cholesterol at each time point.  β, regression coefficient; P-value for  regression 
coefficient. 
b α-tocopherol outcome adjusted for baseline α-tocopherol but not γ-tocopherol. 
Total variability explained (R2)=8%. 
c γ-tocopherol outcome adjusted for baseline γ-tocopherol but not α-tocopherol. 
Total variability explained (R2)=56%. 
d European Americans serve as reference group for race.  
e Never smokers serve as reference group for smoking status. 
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ONLINE SUPPLEMENTAL MATERIALS 
 
Supplemental Methods: 
Supplemental Table 1 Baseline Characteristics of Male Participants Randomized to 
Placebo (n=89) in the RASto SELECTa 
  
Placebo 
(n=89) 
Age (y) 63.3 ± 6.8b 
Ethnicity [n (%)]  
European American 70 (79) 
African American 19 (21) 
Smoking Statusc [n(%)]  
Never 32 (36) 
Former 46 (52) 
Current 10 (11) 
Body Mass Index (BMI), 
kg/m2 
29.0 ± 5.3 
BMId [n(%)]  
Normal 21 (24) 
Overweight 37 (41) 
Obese 31 (35) 
Free cholesterol (mmol/L)e 
2454.4 ± 1239.9 
2171.7(1025.9, 9520.3)f 
 
a Placebo refers to participants taking both placebo pills (vitamin E placebo + selenium 
placebo). RAS, Respiratory Ancillary to SELECT. SELECT, The Selenium and Vitamin E 
Cancer Prevention Trial. 89 of 726 men on placebo had vitamin E assayed. 
b Mean ± SDs. 
c 6 participants missing baseline smoking data (n=1 double placebo, n=1 Vitamin E plus 
Selenium, n=4 Vitamin E plus placebo). 
d Obese defined as BMI ≥30. Overweight defined as BMI 25-30. Normal weight (BMI <25) 
serves as reference group. This sample did not include underweight individuals. 
e Free cholesterol refers to unesterified lipids. 
f Median; minimum, maximum in parentheses.  
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Supplemental Table 2 Plasma Tocopherol Concentration at Thirty-six Months on 
Supplement in Men Randomized to Placebo (N=89) in the RAS to SELECTa 
 
  
Plasma Tocopherol 
at Study Baseline 
Plasma Tocopherol 
at 36 months 
Change in Plasma 
Tocopherolb 
α-tocopherol  
Unadjusted, 
µmol/L 
22.5 ± 11.2c 19.5 ± 8.3 -3.0 ± 7.9 
20.7 
(8.7, 80.8)d 
16.9 
(7.1, 47.5) 
-2.2 
(-44.2, 15.7) 
Adjusted,  
µmol/mmol chol 
9.5 ± 2.9 8.7 ± 2.3 -0.8 ± 2.1 
9.1 
(5.0, 20.9) 
8.5 
(3.6, 15.9) 
-0.5 
(-7.7, 3.4) 
γ-tocopherol  
Unadjusted, 
µmol/L 
3.5 ± 2.8 3.9 ± 3.5 0.4 ± 0.8 
3.0 
(0.2, 20.1) 
3.1 
(0.4, 25.7) 
0.1 
(-6.9, 19.6) 
Adjusted,  
µmol/mmol chol 
1.5 ± 0.9 1.6 ± 0.8 0.1 ± 0.8 
1.5 
(0.1, 5.9) 
1.6 
(0.2, 4.7) 
0.2 
(-2.4, 2.0) 
α-tocopherol/ γ-tocopherol ratio  
11.3 ± 16.5 7.7 ± 7.5 -3.6 ± 15.3 
7.3 
(1.4, 130.1) 
5.5 
(1.8, 47.7) 
-0.89 
(-122.9, 30.4) 
 
a Placebo refers to participants taking both placebo pills (vitamin E placebo + selenium 
placebo). RAS, Respiratory Ancillary to SELECT. SELECT, The Selenium and Vitamin E 
Cancer Prevention Trial. 
b Change in plasma level defined as thirty-six month value minus the baseline value. RAS, 
Respiratory Ancillary to SELECT. SELECT, The Selenium and Vitamin E Cancer Prevention 
Trial. 89 of 726 men on placebo had vitamin E assayed. 
c Mean ± SDs. 
d Median; minimum, maximum in parentheses. 
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Supplemental Table 3 Baseline Plasma Tocopherol Levels in Men Randomized to Vitamin 
E in the RAS to SELECTa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Vitamin E includes all participants on vitamin E (including vitamin E + placebo and 
vitamin E + selenium, n=1166). RAS, Respiratory Ancillary to SELECT. SELECT, The 
Selenium and Vitamin E Cancer Prevention Trial. Values shown are mean ± SDs on first line, 
and median (minimum, maximum)  
b Never smokers n=378, former smokers n=585, current smokers n=185. 
c BMI (kg/m2). Obese defined as BMI ≥30, overweight defined as BMI 25-30, normal weight 
(BMI <25) serves as reference group. This sample did not include underweight individuals. 
 
 
  
 α-tocopherol 
(µmol/mmol chol) 
γ-tocopherol 
(µmol/mmol chol) 
Ethnicity [n (%)]   
European American 
9.2 ± 3.0 
8.6 (4.1, 29.8) 
1.4 ± 0.8 
1.2 (0.1, 6.2) 
African American 
8.1 ± 2.9 
7.4 (3.6, 22.3) 
1.9 ± 0.9 
1.8 (0.1, 5.2) 
Smoking Status [n (%)]b   
Never 
9.1 ± 3.0 
1.3 (0.1, 6.2) 
1.5 ± 0.9 
1.3 (0.1, 6.2) 
Former 
9.1 ± 3.1 
8.4 (4.4, 29.8) 
1.5 ± 0.9 
1.3 (0.1, 5.2) 
Current 
8.0 ± 2.8 
7.3 (4.0, 18.6) 
1.6 ± 0.9 
1.4 (0.1, 4.4) 
Body Mass Index  
(BMI), kg/m2c 
  
Normal 
8.9 ± 3.0 
8.2 (3.6, 21.2) 
1.3 ± 0.9 
1.2 (0.1, 4.5) 
Overweight 
8.9 ± 2.9 
8.3 (4.3, 25.8) 
1.4 ± 0.9 
1.3 (0.1, 5.2) 
Obese 
9.0 ± 3.3 
8.2 (4.0, 29.8) 
1.6 ± 0.9 
1.5 (0.1, 6.2) 
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Supplemental Table 4 Model-based Predicted Change in Plasma Tocopherols (µmol 
α/mmol chol) Among Men Randomized to Vitamin E (400 IU/day all rac-α-tocopherol) in 
the RAS to SELECTa 
 
Variables in 
Model 
Predicted Change in Plasma α-
Tocopherol (µmol/mmol chol) 
Predicted Change in Plasma γ-
Tocopherol (µmol/mmol chol) 
 European 
American 
African 
American 
European 
American 
African 
American 
Smoking Status     
Never 4.1 ± 1.1b 
4.3 (-0.2, 5.8) 
3.2 ± 1.2 
3.4 (-1.5, 4.9) 
-0.6 ± 0.6 
-0.5 (-4.1, 0.3) 
-0.8 ± 0.6 
-0.7 (-2.6, 0.5) 
Former  4.1 ± 1.1 
4.2 (-3.4, 5.8) 
3.0 ± 1.1 
3.4 (-1.9, 4.6) 
-0.6 ± 0.6 
-0.5 (-3.9, 0.3) 
-0.8 ± 0.7 
-0.7 (-3.2, 0.3) 
Current 3.8 ± 1.1 
4.0 (0.2, 5.5) 
3.1 ± 0.8 
3.3 (0.9, 4.3) 
-0.6 ± 0.6 
-0.4 (-2.4, 0.3) 
-0.7 ± 0.7 
-0.7 (-2.6, 0.5) 
 
1 Vitamin E includes all participants on vitamin E (including vitamin E + placebo and 
vitamin E + selenium, n=1166). RAS, Respiratory Ancillary to SELECT. SELECT, The 
Selenium and Vitamin E Cancer Prevention Trial. Change in plasma level defined as thirty-
six month value minus the baseline value. All tocopherol values adjusted for free 
cholesterol at each time point. Unless otherwise noted, models predicting change in α-
tocopherol adjust for baseline α-tocopherol level, and models predicting change in γ-
tocopherol adjust for baseline γ-tocopherol level. Models adjusted for all other variables, 
including smoking status, smoking dose, years smoked, age, race, and BMI. bValues shown 
are mean ± SDs on first line, and median (25th percentile, 75th percentile)  
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Supplemental Table 5 Regression Coefficients from Mixed Models (Unadjusted Models) 
for Change in Plasma α- and γ-tocopherol (µmol/mmol chol) for Male Participants 
Randomized to Vitamin E in the RAS to SELECTa   
 
Variables Change in Plasma -
Tocopherolb 
Change in Plasma γ-
Tocopherolc 
  P-value  P-value 
Baseline -tocopherol -0.3308 (<0.0001) 0.0147 (0.0094) 
Baseline γ-tocopherol  1.0645 (<0.0001) -0.6868 (<0.0001) 
Raced   
African American -1.33 (<0.0001) 0.2569 (<0.0001) 
European American Reference  - - - 
Age 0.0268 (0.1516) -0.0048 (0.0688) 
Smoking Statuse Type III p-value=0.1000  
Current Smokers -0.7426 (0.0439) 0.1295 (0.0122) 
Former Smokers -0.0634 (0.8130) 0.0083 (0.8252) 
Never Smokers Reference - - - 
Smoking Dose -0.0269 (0.0776) 0.0049 (0.0220) 
Years Smoked -0.0037 (0.6066) 0.0004 (0.6862) 
Body Mass Index 
(BMI), kg/m2 
0.0526 (<0.0001) 0.0029 (0.4216) 
BMI Categoryf Type III p-value=0.3776 Type III p-value=0.1883 
Obese 0.4624 (0.1771) 0.0481 (0.3221) 
Overweight 0.2136 (0.5123) -0.0211 (0.6450) 
Normal weight Reference - - - 
 
a Vitamin E includes all participants on vitamin E (including vitamin E + placebo and 
vitamin E + selenium, n=1166). RAS, Respiratory Ancillary to SELECT; SELECT, The 
Selenium and Vitamin E Cancer Prevention Trial. Change in plasma level defined as thirty-
six month value minus the baseline value. All tocopherol values adjusted for free 
cholesterol at each time point. Models adjust for baseline tocopherol level unless otherwise 
noted. β, regression coefficient for each variable adjusted only for baseline tocopherol 
(unadjusted for other variables); P-value for  regression coefficient. 
b α-tocopherol outcome adjusted for baseline α-tocopherol but not γ-tocopherol.  
c γ-tocopherol outcome adjusted for baseline γ-tocopherol but not α-tocopherol. 
d European Americans serve as reference group for race.  
e Never smokers serve as reference group for smoking status. 
f Obese defined as BMI ≥30. Overweight defined as BMI 25-30. Normal weight (BMI <25) 
serves as reference group. This sample did not include underweight individuals. 
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Abstract 
Background Randomized controlled trials are the gold-standard for tests of hypothesis, 
however in order to fully assess the effect of an intervention intent-to-treat analyses are 
complemented by as-treated and plausibility analyses.   
Methods Using data from the Respiratory Ancillary Study (RAS) to the Selenium and 
Vitamin E Cancer Prevention Trial (SELECT), we investigated the effects of baseline 
selenium nutriture on the effect of selenium supplementation (200 µg/day L-
selenomethionine) on rate of decline in lung function. Plasma selenium was assessed in 
2,681 men at study baseline, prior to supplementation, and rate of decline in lung function 
was assessed by longitudinal spirometry measures over approximately three years.  
Results Treatment with selenium had no effect on rate of decline in the forced expiratory 
volume in the first second (FEV1), and considering baseline nutriture there was no effect 
even in men with lower baseline selenium. Furthermore, in the untreated placebo arm 
there was no association of baseline selenium with rate of decline in lung function.   
Conclusions Selenium does not attenuate rate of decline in lung function, with or without 
consideration of baseline nutriture. The higher overall baseline distribution of selenium in 
this study (mean 170 ng/mL, SD 28) precludes a complete assessment of selenium effects 
in a sample with low selenium.  
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Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is an important cause of morbidity 
and mortality in the United States(1), and its prevalence is increasing(2). An imbalance in 
oxidant-antioxidant levels is proposed to play a key role in the pathogenesis of COPD, and 
individuals with COPD have higher levels of oxidative stress. Nutrients with antioxidant 
properties, including selenium(3), are hypothesized to play a role in preventing and/or 
attenuating oxidative stress-related diseases, including COPD. Some nutrients, in particular 
selenium, are only modifiable through supplementation because of variation in food 
sources and/or lack of specific information on nutrient content of foods, thus 
supplementation remains a viable method to mitigate oxidative damage and reduce disease 
risk. Currently available therapies for COPD show only modest benefits in ameliorating 
symptoms, and most treatments do not slow the rate of decline in lung function that is the 
hallmark of this disease(4-6), highlighting the important need for novel preventive and 
therapeutic approaches, including nutritional modification.  
The key symptom of COPD is rapid decline in lung function, and lung function, 
measured by spirometry, is the cornerstone of COPD diagnosis and severity staging. The 
Respiratory Ancillary Study (RAS) to the Selenium and Vitamin E Cancer Prevention Trial 
(SELECT) investigated the effect of intervention with vitamin E and/or selenium on rate of 
decline in lung function and reported no effect of selenium on rate of decline(7). This 
randomized trial was null in spite of strong cross-sectional evidence that higher plasma 
selenium was associated with better lung function in NHANES III(8). Prior clinical trials of 
selenium identified a selenium nutriture threshold, below which effects of selenium 
supplementation on cancer risk were evident(9). The question of whether response to 92
intervention is modified by baseline level of the nutrient comprising the intervention is a 
key question, with important implications for all trials of nutrient supplementation(10, 11), 
and is a key consideration in the context of interpretation of null results from randomized 
trials.  
Selenium has antioxidant functions and is a constituent in protective enzymes and 
amino acids, including selenocysteine and selenomethionine(12). Higher selenium status 
was associated with lower levels of oxidative stress biomarkers in observational 
studies(13), but findings from selenium intervention studies were mixed(14-16). Only a 
handful of past studies assess the association of selenium with lung outcomes, but there is 
evidence for protective associations for lung function(8) and asthma risk(17-19).  
Considering that prior studies of selenium int(19)ervention found effects were 
limited to individuals with low baseline selenium status(20), we investigated similar 
hypotheses in the RAS. Thus, we sought to complete a more comprehensive investigation of 
the effect of supplements, beyond the intent-to-treat model in the main analysis of the 
trial(7).  Using baseline nutriture, measured as plasma selenium concentration in pre-
randomization blood samples, we investigated whether baseline selenium nutriture 
modified the effect of selenium supplementation on rate of decline in lung function. 
 
Methods 
Study Population 
The Respiratory Ancillary Study (RAS) to the Selenium and Vitamin E Cancer 
Prevention Trial (SELECT) investigated the effects of vitamin E and selenium on the annual 
rate of decline in pulmonary function.  SELECT was a prostate cancer primary prevention 
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trial which randomized 35,433 male participants ages fifty and older at 428 study sites in 
North America to four arms: 400 IU/day α-tocopherol  (all rac-α-tocopheryl acetate, 
hereafter referred to as vitamin E) plus selenium placebo; vitamin E placebo plus 200 
µg/day selenomethionine (L-selenomethionine, selenium); both active supplements; or, 
vitamin E placebo plus selenium placebo(21). Cigarette smokers were preferentially 
recruited to the RAS given their higher risk for steeper lung function decline(7). 
Using a post-randomization design, the RAS studied multiple pulmonary function 
parameters: forced expiratory volume in the first second (FEV1), forced expiratory flow at 
25 to 75% of the forced vital capacity (FVC) (FEF25-75); and the ratio of FEV1/FVC. The 
informative pulmonary function parameters are indicators of irreversible airflow 
limitation, which occurs in individuals with COPD.  
Measurements 
Spirometry was completed following The American Thoracic Society (ATS) 
guidelines(22), using a handheld electronic spirometer (EasyOne, ndd Medizintechnik, 
MA). Pulmonary function was assessed about once per year, at least three times over four 
years, however early withdrawal of supplement on October 23, 2008 resulted in fewer 
assessments during the supplemented period; pulmonary function tests prior to March 1, 
2009 were considered to reflect treatment effects on the rate of decline. Pulmonary 
function testing was under strict quality control, and details are reported elsewhere(7). 
 Sample preparation and analysis for selenium was performed at the USDA Plant, Soil 
and Nutritional Research Unit, Cornell University, Ithaca, NY. A 2% nitric acid solution was 
prepared using concentrated nitric acid from a Teflon sub-boiling still and double-
deionized water, resistivity > 18 MΩ cm. Plasma samples were prepared for selenium 94
analysis by adding 5 mL of 2% HNO3 to 100 µL of plasma (thawed on ice). Assessment of 
accuracy and precision were determined by assaying a 10 ng/mL reference standard and a 
mixed plasma control sample periodically throughout all sample runs. The mixed plasma 
control samples were prepared in the same way as the plasma samples. An Agilent 7500 
cs/ce quadrupole inductively coupled plasma-dynamic reaction cell-mass spectrometry 
(ICP-MS) equipped with a dynamic reaction cell was used to determine selenium 
concentration in plasma samples. The ion intensity at m/z 78 was used to monitor Se and 
Germanium at m/z 72 was used as an internal standard. Data were collected using the 
Spectrum mode for direct analysis. Maximum sensitivity was obtained by daily tuning of the 
ion lens system, gas flow rates, and other parameters. Samples were run manually with 
continuous quality monitoring.  
Statistical Methods  
All analyses were carried out in SAS, version 9.3 (SAS Institute, Cary, NC). Age, 
height, time (elapsed years) and lung function were continuous variables, and smoking 
status, race/ethnicity, and treatment arm were categorical variables. Baseline selenium 
was considered as a continuous variable; in addition, we also categorized selenium into 
quartiles and tertiles, assessing both linear trends and non-linear associations. 
Hierarchical linear regression models (mixed models) estimated the effect of 
intervention on repeated measurements of lung function, and mediation by baseline 
nutriture was assessed by adding an interaction term between baseline plasma selenium, 
treatment, and time. Refer to Appendix for further details on model selection and checking. 
 
Results 
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 Plasma selenium was assayed in blood samples collected at SELECT baseline (pre-
randomization) for 2,681 participants in the RAS; among these men, 38% reported use of a 
supplement containing selenium in the year prior to randomization. The mean age was 63 
(SD 6) years, 22% were African American, and 16% of participants were current smokers; 
participant characteristics did not vary by treatment arm (Table 1). 
 At the baseline, the mean plasma selenium concentration was 170 (SD 28) ng/mL, 
and there were no differences by treatment arm (Table 1). Using a definition of low 
selenium, which was developed in the Nutritional Prevention of Cancer Study (Se < 123.2 
ng/mL= low selenium)(9), only 1.6% of the RAS participants had low selenium (data not 
shown). Considering the distribution of baseline plasma selenium concentration across all 
RAS participants with measurements, the mean of each quintile (minimum, maximum) 
was: quintile I, 138 (90, 149); quintile II, 156 (149, 163); quintile III, 168 (163, 174); 
quintile IV, 181 (174, 189); and quintile V, 210 (189, 459) ng/mL. 
Effect of baseline nutriture on treatment effect 
 The effect of treatment on rate of decline in lung function did not differ by baseline 
plasma selenium concentration (Table 2). A comprehensive analytic approach considered 
the effect of any selenium (selenium alone or selenium + vitamin E) compared to placebo, 
the effect of selenium alone compared to placebo, and the effect of selenium + vitamin E 
compared to placebo. Findings were the same whether selenium was considered as a 
continuous variable (ng/mL) or as a categorical variable, coded as ordered categories or as 
a nominal variable. Categorical models considered low selenium versus selenium replete 
groups, and either tertiles of quintiles of the distribution. The low selenium models were 
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under-powered given only 1.6% of men had low selenium using definitions identified in 
prior studies of chronic disease outcomes.  
 Given that treatment with vitamin E attenuated the rate in decline in FEV1, models 
considering effect modification by baseline selenium nutrition in the test of selenium + 
vitamin E placebo versus placebo + placebo are preferred because they are unaffected by 
vitamin E supplementation. Findings for all models considered (Table 2) are consistent; 
there is no evidence for effect modification by baseline selenium nutriture (p-values for 
model tests of effect modification are shown in Table 2), and, furthermore, the model 
coefficients do not reveal any evidence for effect modification that is of an interesting 
magnitude and/or in the hypothesized direction. 
Effect of baseline plasma selenium on cross-sectional lung function and rate of decline  
 Men in the placebo only arm (n=658) were studied to investigate the association of 
baseline plasma selenium concentration with lung function, independent of any effects of 
treatment, and considering both the cross-sectional and longitudinal outcomes. Selenium 
was treated as both as a continuous and categorical variable in these analyses. There was 
no evidence that starting plasma concentration of selenium was associated with 
subsequent rate of decline in FEV1 in men in the double placebo arm (Table 3). 
 
Discussion 
There was no evidence for effect modification by usual selenium nutrition; thus, the 
effect of selenium intervention on rate of decline in FEV1, which was null overall, did not 
differ by usual selenium nutriture. Neither was there evidence that usual selenium 
nutriture was associated with the subsequent rate of decline in FEV1 in the untreated 
placebo group. This paper resolves the possibility of differential potential to benefit in the 97
interpretation of the null result for selenium in the RAS(7). While past findings from 
observational studies supported a positive association of plasma selenium with lung 
function(8), the randomized placebo-controlled design, as used herein, allows for a 
stronger test of the hypothesis for an effect of selenium, and both the intent-to-treat and 
the potential to benefit analysis are clearly null. 
NHANES III findings supported a clear and strongly positive cross-sectional 
association of serum selenium with lung function (8), but in RAS analyses limited to the 
placebo arm there was no cross-sectional association of plasma selenium concentration 
with lung function. Furthermore, selenium alone did not lower in vivo oxidative stress, as 
indicated by effects on a urine biomarker (F2-isoprostanes) in a previous study of 
participants in the RAS(16).  
A recent workshop on evidence-based nutrition emphasized that need to carefully 
consider the randomized controlled trial design for investigation of nutrient-disease 
questions because of the inability to identify and use a truly unexposed (no intake) control 
group(10). SELECT, however, supplemented with pharmacological doses of selenium(21), 
which led to plasma concentrations above those obtained through dietary manipulation 
alone. Furthermore, a specially formulated multivitamin was provided to SELECT men and 
their spouses to ensure that self-supplementation with multivitamins, which is common in 
the United States, did not include the study nutrients. Thus, nutrient intake in the active 
treatment groups was expected to derive mainly from the study supplement, and intake 
was therefore far above the dietary intake in the placebo group, allowing for a strong test of 
hypothesis.  
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A second point in using the randomized trial design to study nutrient intervention is 
the concept of potential to benefit(10). The evidence base that identifies the optimal level 
of nutrients for the prevention of chronic disease is weak, and thus in identifying and 
registering trial participants there is no screening for nutritional status, nor any 
consideration of usual nutriture for the supplemented nutrients. In the case of the RAS and 
SELECT, men were right-shifted in their distribution of selenium nutriture; median levels 
were 168 and 135 ng/mL(21), respectively. Only 1.6% of RAS men were below thresholds 
established in a prior study as representing thresholds below which intervention would be 
expected to have positive benefits(9).  Similarly, in comparing the distribution of selenium 
in the RAS participants to the distribution of selenium in NHANES III adult participants, 
there is far less variability in the RAS and this may contribute to the null findings; the 
average selenium reported in NHANES III was 123 ng/mL (SD 17) (8), confirming the right-
shift in the RAS distribution of plasma selenium at baseline (mean 170 ng/mL (SD 28)). Of 
note, selenium values in NHANES(8) III used the atomic absorption spectrophotometry 
method, however a more recent analysis among adults ≥40 years old in NHANES 2003-
2004 reported a mean selenium of 136.7 ng/mL and also used ICP-MS(23). The high levels 
of baseline plasma selenium in RAS are not, therefore, an artifact of the laboratory assay, as 
RAS and NHANES 2003-2004 both utilized ICP-MS. 
The data used herein possess many of the qualities, put forth by Blumberg et al(10), 
which enhance certainty of randomized controlled trial results; these qualities include 
minimal loss of sampling units, due to high retention in SELECT and RAS. These data also 
allow for adequate contrast in intake between the intervention and control group, since 
SELECT provided participants with a free multivitamin, free of the nutrients under study, 99
for the man and their spouse(21), thus ensuring that selenium intake at or near 
supplemented ranges for selenium was limited to the active treatment arms. 
The data utilized herein to investigate the association between baseline selenium 
and lung function, including and excluding the effect of treatment, is valuable given 
longitudinal lung function measurements, long-term supplementation, and inclusion of 
African Americans and smokers. The null findings are similar to and extend the previously 
reported findings for the full RAS study(7); thus, we can now conclude that selenium does 
not attenuate rate of decline in lung function with or without consideration of baseline 
selenium nutriture. This study cannot rule out the possibility that persons with low 
baseline selenium, as defined in past studies(9), benefit from supplementation with 
selenium; too few participants in RAS were below this level to allow a test of this 
hypothesis. 
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Table 1 Baseline Characteristics of Study Participants in the RAS to SELECTa 
Characteristics 
Placebo 
(n=658) 
Selenium 
(n=702) 
Age at SELECT randomization, 
years [n(%)] 63 (7) 63 (6) 
Race/ethnicity [n(%)]  
 African American 134 (20) 165 (24) 
European American/Other 524 (80) 537 (76) 
Smoking status[n(%)]b  
 Never/Former 550 (84) 600 (85) 
Current 103 (16) 97 (14) 
Selenium Supplement Use [n(%)]  
 0 (none) 394 (60) 427 (62) 
≥50 IU 57  (9) 53 (8) 
≥ 200 IU 9 (1) 8 (1) 
Low Plasma Selenium  
Pre-randomization 
(<11.6 ng/mL) [n(%)] 8 (1) 17 (2) 
Plasma Selenium  
Pre-randomization (ng/mL) 
Quintile:c 
1 139 (9) 137 (12) 
2 156 (4) 157 (4) 
3 169 (3) 168 (3) 
4 181 (4) 181 (4) 
5 210 (35) 209 (23) 
Plasma Selenium  
Pre-randomization (ng/mL) 
Tertile:c   
1 144 (10) 143 (13) 
2 168 (6) 168 (5) 
3 199 (30) 198 (22) 
aRAS, Respiratory Ancillary Study; SELECT, Selenium and Vitamin E Cancer Prevention 
Trial; 2,681 men with selenium assayed at SELECT baseline by ICP-MS method (n=658 
placebo, 702 selenium; 667 vitamin E and 654 vitamin E plus selenium, not shown). Mean 
(standard deviation) unless otherwise noted 
bParticipants missing smoking: n=5 selenium, n=5 placebo arm 
cQuintiles and tertiles cutpoints from the full distribution of participants with selenium 
assayed (n=2,681 across all four treatment arms) 
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Table 2. Effect Modification by Baseline Selenium of Selenium Treatment Effect on Rate of 
Decline in FEV1 in the RAS to SELECT: Selenium only versus Placebo onlya 
Baseline Plasma Selenium P-Valueb 
Continuous variable 0.7050 
Quintile variablec  
Continuous 0.4138 
Categoricald 0.5962 
Tertile variablee  
Continuous 0.7777 
Categoricald 0.8372 
aRAS, the Respiratory Ancillary Study; SELECT, Selenium and Vitamin E Cancer Prevention 
Trial; models shown are Se only (no vitamin E) compared to placebo (neither Se or vitamin 
E) 
bP-value shown for interaction terms from hierarchical linear mixed models; 3-way 
interaction of time * treatment * baseline selenium  
cQuintiles of baseline selenium defined by cutpoints: 149, 162, 173, 188 ng/mL. 
dType III p-value 
eTertiles of selenium defined by cutpoints 158, 178 ng/mL. 
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CHAPTER 5 
CONCLUSION 
A randomized controlled trial is considered to be the gold-standard for the test of a 
hypothesis, however analyses beyond intent-to-treat are needed to fully consider the 
plausibility of intervention effects, particularly in the context of null findings(1). Sample 
characteristics and mechanisms of action are two important considerations for the 
interpretation of intervention effects. The analyses described herein utilized data from the 
Respiratory Ancillary Study (RAS) to the Selenium and Vitamin E Cancer Prevention Trial, a 
long-term randomized placebo-controlled trial of men assigned to vitamin E (400 IU/day 
all rac-α-tocopheryl acetate) and/or selenium (200 µg/day L-selenomethionine). While 
RAS found no effect of selenium on rate of decline in lung function, a non-statistically 
significant main effect of vitamin E to attenuate rate of decline in lung function, and a 
statistically significant effect of vitamin E in cigarette smokers (2), this dissertation further 
investigated the plausibility of effects of these nutrients in a three-tiered approach. First, 
effects of intervention on a biomarker of oxidative stress were assessed; secondly, we 
considered associations between participant characteristics and change in plasma vitamin 
E levels; and, finally, we considered whether there was an effect of selenium on rate of 
decline in lung function in men with low baseline selenium nutriture.  
The RAS data allowed for a strong test of these hypotheses given the randomized 
trial design, long-term supplementation, and longitudinal pulmonary function 
measurements, and thus the investigations presented in this dissertation address gaps in 
the literature by improving upon by considering effects of these nutrients more completely. 
Sample characteristics are also a strength of this study; African Americans, traditionally 105
under-represented in epidemiological studies, were intensively recruited by SELECT and 
comprised 24% of RAS participants(2). Furthermore, purposeful oversampling of cigarette 
smokers by RAS (16% current smokers, 48% former smokers)(2) allowed for detection of 
effects of treatment on an oxidative stress biomarker, given that smokers have higher 
levels of oxidative stress and thus had greater potential to benefit from intervention.  
Effect of Vitamin E and Selenium on Urine F2-Isoprostanes, A Biomarker of Oxidative Stress  
While vitamin E and selenium have antioxidant properties, few studies have 
investigated the effect of these nutrients on an oxidative stress biomarker, and none have 
investigated mediation of effects on a functional outcome such as lung function by an 
oxidative stress biomarker. This dissertation provides definitive evidence that vitamin E 
lowers a biomarker of oxidative stress and offers a stronger test of this hypothesis in 
comparison to previous small non-randomized studies reporting mixed results. 
Furthermore, the urine F2-Isoprostane biomarker is considered the gold-standard for 
assessing in vivo oxidative stress, and many previous studies utilized biomarkers and 
specimen types that may reflect ex vivo processes. Selenium had no effect on F2-
Isoprostanes, consistent with its lack of effect on rate of decline in lung function(2). Lack of 
association between lowering of F2-Isoprostanes and effect of vitamin E on rate of decline 
in FEV1 may reflect the need for a more lung tissue-specific biomarker, as F2-Isoprostanes 
are reflective of systemic lipid peroxidation. 
The Response to Vitamin E Supplementation in the Respiratory Ancillary Study to SELECT 
 While vitamin E is posited to have beneficial health effects, and thus 
supplementation is suggested as a potential treatment or preventive agent, little is known 106
about the individual response to supplementation. Variability in plasma tocopherol levels, 
particularly the range observed in individuals consuming supplements(5) suggests that 
there is significant between-individual variability in plasma change in response to vitamin 
E supplementation. While several large randomized controlled trials of vitamin E showed 
no benefit on on health endpoints, achieved plasma vitamin E levels in response to 
supplementation were rarely considered. Recent studies have identified genetic variants 
that affect usual plasma vitamin E concentration(6) and response to vitamin E 
supplementation(7), however the data addressing plasma response is very limited. This 
dissertation addresses a gap in the literature by assessing associations between individual 
characteristics and plasma response to supplementation within a long-term, randomized 
control trial of a diverse sample including a large percentage of African Americans and 
cigarette smokers. Furthermore, use of the GC-MS methodology allowed for consideration 
of both alpha(α)-tocopherol and gamma(γ)-tocopherol; γ-tocopherol is increasingly under 
study in relation to bioactivity and health outcomes, but, as yet, very few papers are 
published on this topic. Since α-tocopherol and γ-tocopherol both use the same transfer 
protein (α-tocopherol transfer protein , α-TTP)(8), levels in the plasma are inversely 
correlated. Due to this inverse association, and considering that α-tocopherol 
supplementation causes a reduction in plasma γ-tocopherol levels, addressing plasma 
levels of α-tocopherol in comparison to γ-tocopherol is a more complete characterization of 
the effects of supplementation on plasma nutriture. 
Race was identified as the most important predictor of change in plasma α-tocopherol and 
γ-tocopherol levels; in response to vitamin E supplementation over three years, African 
Americans had lower baseline α-tocopherol and less of an increase, and lower γ-tocopherol 107
with less of a decrease, compared to European Americans. This suggests that African 
Americans may benefit less from intervention, given that the effect of vitamin E on lung 
outcomes is proposed to act locally at target tissue and this nutrient must be carried in the 
plasma to the target tissue. It is unclear, however, whether the lower changes in response 
to supplementation indicates lower potential to benefit from intervention. A second 
possibility, which cannot be addressed by this dissertation, is that African Americans are 
using more of the supplemental vitamin E, and thus vitamin E is ‘used up’ leading to lower 
concentrations in plasma. If the latter scenario is correct, African Americans may actually 
have more potential to benefit from intervention; in the study of the oxidative stress 
biomarker, African Americans had higher levels of urine F2-Isoprostanes, contributing 
some evidence to the plausibility of this hypothesis. Adjustment for cholesterol and other 
covariates, including smoking status and body mass index, indicate that the effect of race is 
robust and should be considered in future studies of vitamin E intervention. The 
Contribution of Baseline Nutriture To Intervention Effects in a Randomized Controlled 
Trial 
Given that there was no effect of selenium on rate of decline in lung function in 
RAS(2), we undertook a plausibility analysis of selenium effects in men with lowest 
selenium levels at baseline, who were hypothesized to have the greatest potential to 
benefit from intervention. The null finding from the overall RAS(2) was thus further 
considered, and we tested whether treatment effects for selenium differed by baseline 
selenium nutriture, which was modeled as a continuous variable (ng/mL plasma 
concentration) and a categorical variable (deficiency, and percentiles). There was no 
evidence for an effect of selenium intervention on rate of decline in forced expiratory 108
volume in the first second(FEV1)with consideration of baseline selenium levels. 
Additionally, there was no association between selenium nutriture at study baseline and 
rate of decline in lung function in this sample.  
While it is evident that selenium has no effect on lung function in these men, it is 
important to note that this sample had a right-shifted distribution of baseline selenium in 
comparison to a prior study of selenium and lung function(3), and only 1.6% of men were 
selenium deficient according to a cut-point of selenium deficiency identified by a previous 
study of selenium supplementation and cancer(4). It remains a possibility, therefore, that 
selenium intervention may have a beneficial effect in men with lower selenium levels, but 
this hypothesis could not be fully assessed in this dataset given the overall high levels of 
selenium nutriture. 
Significance and Future Directions 
 Vitamin E deserves further study as a potential treatment or preventive for 
oxidative stress-related health outcomes, including Chronic Obstructive Pulmonary Disease 
(COPD) given the suggested effects on lung function. There is no effect of selenium on an 
oxidative stress biomarker, nor on lung function, however assessment of effects in a sample 
with lower baseline selenium would enhance our understanding of associations between 
selenium and oxidative stress. Randomized controlled trials are the gold-standard study 
design, and offer the benefit of reducing the effect of confounding, particularly as trial size 
increases; however, analyses beyond intent-to-treat analyses add to our understanding of 
intervention effects and make full use of the large investment needed to produce such 
datasets. Future studies should assess baseline nutriture as well as the biokinetics of 109
plasma response to supplement interventions to gain a better understanding of effects on 
health endpoints. 
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CHAPTER 6 
APPENDIX 
Selection and Checking of the Mixed Model: 
The Respiratory Ancillary Study (RAS) longitudinal dataset was limited to 
pulmonary function tests (PFTs) prior to March 1, 2009 to approximate the supplemented 
period. Supplementation ended on October 23, 2008 but we are conservatively allowing for 
the possibility of effects of supplement four months beyond supplement withdrawal. 
Standard quality control criteria, as detailed by the American Thoracic Society{{229 
American 2005;}}, were applied to the dataset; tests not meeting start or end of test criteria 
or reproducibility were eliminated. The resulting dataset had 6,548 PFTs. 
Different variance-covariance matrices were investigated, including unstructured, 
heterogeneous autoregressive, heterogeneous compound symmetry, heterogeneous 
toeplitz, variance components, autoregressive, and compound symmetry. A basic model 
including only elapsed time (months) to predict FEV1 was run under each variance-
covariance matrix variation by altering the type option in the mixed model in SAS.  AIC 
criteria and degrees of freedom were compared, and variance components was selected as 
the best choice for this longitudinal dataset given that it had a relatively small AIC value 
(92500.7) combined with the smallest number of degrees of freedom for the Likelihood 
Ratio Test (df=1). While some other choices, including unstructured, had smaller AIC 
values (unstructured, heterogeneous autoregressive, heterogeneous compound symmetry, 
heterogeneous toeplitz all had AIC of 92487.9), these models also had a greater number of 
degrees of freedom (df=3), thus variance components was a more parsimonius choice 112
given that it describes the structure just as well but with fewer parameters (since it 
assumes no correlation).  Variance components models a different variance component for 
each random effect(1).  
The Kenward-Rodgers method for standard error and denominator degrees-of-
freedom (ddfm) correction was selected (ddfm=kr) for computing the denominator 
degrees of freedom for the tests of fixed effects; this method inflates the estimated 
variance-covariance matrix of the fixed and random effects and may shrink the standard 
error(2). 
Previous experience with longitudinal pulmonary function datasets strongly 
suggested that reasonable rate of decline estimates could only be obtained with measures 
separated by a minimum of two years, and thus we eliminated additional pulmonary 
function tests (beyond the baseline PFT) from participants with less than two years from 
first to last PFT; baseline PFTs remained in the dataset for these participants, and thus they 
still contributed information to the model. 
Residuals were studied using a basic mixed model, independent of the effect of 
treatment; the mixed model was used to predict rate of decline in FEV1, and time (elapsed 
months), age, height, and race were included as independent variables. Due to memory 
limitations in SAS related to the complexity of our longitudinal dataset, in order to output a 
dataset of residuals we were required to change the ddfm option to bw (between and 
within method), versus the Kenward Rogers method we had selected. 
In comparing parameter estimates between the simple model using ddfm=bw and 
ddfm=kr, there were negligible differences in parameter estimates and thus use of 113
ddfm=bw to identify outliers is arguably sound. Studentized residuals were plotted against 
the predicted values (Figure 1), and no discernible pattern was detected; residual plots 
were comparable across treatment arms (data not shown). 
Outliers, identified as observations (single pulmonary function tests) beyond a 
studentized residual value of ±3, were eliminated from the dataset. This process continued 
iteratively until no outliers remained. Once all outliers were identified and eliminated (116 
outliers eliminated of the initial 6,548 observations), we again eliminated additional 
pulmonary function tests (beyond the baseline PFT) from participants with less than two 
years from first to last PFT to allow for more precise estimation of rate of decline (33 
PFTs), resulting in a total of 6,397 PFTs. The effect of treatment was estimated in datasets 
that included and excluded outliers, and parameter estimates were comparable; the dataset 
excluding outliers more precisely estimated the effect of treatment, as evidenced by lower 
standard errors (data not shown). 
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 Figure 1. Studentized Residuals Compared to Predicted Values 
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